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Abstract 
 
Background: As the leading cause of mortality in Switzerland and many other developed 
countries, cardiovascular disease (CVD) is of high significance in public health: In 2003, CVD 
was the leading cause of death in Switzerland, accounting for 38% of adult deaths. Heart 
rate variability (HRV) is a subclinical electrophysiologic marker of cardiac autonomic control 
and lower HRV is associated with higher CVD morbidity and mortality. Thus altered HRV 
may signify autonomic dysregulation, and study of factors influencing HRV may inform 
epidemiologic and clinical evaluation of pathways ultimately leading to cardiac morbidity and 
mortality. Literature on HRV in the general population and its influencing factors is relatively 
scarce. Literature on HRV in the general population and its influencing factors is relatively 
scarce. 
Aims: This thesis presents normal values of HRV for the Swiss population and describes its 
determinants. As an example of an environmental risk factor, we study the influence of 
passive smoking on HRV and possible mechanisms. A further aim of the thesis is to describe 
the impact of obesity and a sedentary lifestyle as personal risk factors on HRV and to look at 
modification of the effect of obesity by physical exercise. 
Methods: Between 2001 and 2003, we measured time and frequency domain parameters of 
HRV in a random sample of the SAPALDIA (Swiss cohort study on Air Pollution and Lung 
Diseases in Adults) cohort participants aged 50 to 72 using digital 24-hour electrocardiogram 
recordings. Subjects with recordings of less than 18 hours, atrial fibrillation, recent 
anaesthesia or myocardial infarction or subjects taking digitalis were excluded, and 
recordings of insufficient quality discarded, leaving 1742 recordings for analyses. Health 
status and personal risk factors were assessed in a detailed interview. Blood pressure, 
height and weight as well as markers of cardiovascular health in the blood were measured. 
To assess effects of different risk factors on HRV, a structured multivariable linear regression 
was performed. To estimate percentiles of gender specific HRV parameters as a function of 
age, subjects with known risk factors (smoking, history of cardiovascular disease, high blood 
pressure, diabetes, medication) were excluded. In multivariable regression analyses, we 
determined the effect of environmental tobacco smoke on HRV, heart rate and blood 
pressure. We estimated the effect of physical activity and BMI on HRV in multivariable 
regression analyses and investigated the interaction between those two variables. 
Results: Taking into account the effects of age, lifestyle factors, variables of cardiovascular 
health, medication and cardiovascular risk factors in the blood, women had a lower HRV than 
men. The age dependent decline of HRV differed between the sexes. High blood pressure, 
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current smoking, higher levels of uric acid, high-sensitive C-reactive protein and non-HDL-
cholesterol were independently associated with lower HRV. 
Non-smoking subjects exposed to tobacco smoke pollution at home or at work for more than 
2 hours/day had lower HRV values than unexposed subjects. We also found a higher heart 
rate in exposed subjects and a tendency for higher diastolic blood pressure. 
Obese subjects exercising regularly 2 hours per week or more had higher HRV than their 
sedentary peers. Regardless of weight, the improvement of HRV was greatest for those who 
exercised regularly. Subjects having gained weight over the past 11 years who were 
exercising at least moderately had increased HRV values compared to subjects not 
exercising. Exercising regularly significantly modified the relation of obesity with HRV. 
Conclusions: HRV shows independent associations with a great variety of known personal 
and environmental cardiovascular risk factors. These findings help elucidate cardiac 
autonomic pathways through which factors such as passive smoke exposure and inactivity 
may adversely influence cardiac morbidity and mortality. As such, the findings strengthen 
scientific understanding of the etiology of cardiac disease, and may be useful in the 
development of public health strategies to protect and improve cardiovascular health.
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Zusammenfassung 
 
Hintergrund: Kardiovaskuläre Krankheiten (KVK) sind in der Schweiz sowie in vielen 
anderen Industriestaaten die Todesursache Nummer eins und sind somit äusserst wichtig für 
Public Health. Bei 38% der im Jahr 2003 in der Schweiz Verstorbenen, waren KVK die 
Haupttodesursache. Für Herzinfarkt und auch für kardiovaskuläre Krankheiten sind zwar 
bereits klassische Risikofaktoren beschrieben, doch könnten früher messbare Indikatoren 
der Herzfunktion für die epidemiologische und gesundheitsbezogene Forschung wertvoll sein 
und als klinische Hilfsmittel dienen. Die Herzrhythmusvariabilität (HRV) wird durch das 
autonome Nervensystem reguliert. Frühere Forschungsresultate zeigten, dass tiefere HRV-
Werte sind mit erhöhter kardiovaskulärer Morbidität und Mortalität assoziiert sind. Über 
bevölkerungsbezogene Untersuchungen zur Verteilung von HRV und deren Einflussfaktoren 
wurden bisher wenig publiziert. 
Ziele: Diese Dissertation beschreibt zunächst Normwerte für die HRV in der Schweizer 
Bevölkerung und analysiert Faktoren, die deren Verteilung beeinflussen. Als Beispiel eines 
Umweltfaktors untersuchen wir den Einfluss von Passivrauchen auf HRV sowie 
Mechanismen. Das dritte Ziel der Dissertation ist, den Einfluss von Adipositas und sitzendem 
Lebensstil als persönliche Risikofaktoren auf HRV zu beschreiben und zu untersuchen, ob 
körperliche Aktivität die Auswirkung von Adipositas auf HRV verändert. 
Methoden: Zwischen 2001-2003 haben wir mit digitalen 24-Stunden-Elektrokardiogramm-
aufzeichnungen Zeit- und Frequenzbereichsparameter der HRV in einer Zufallsstichprobe 
von 50 bis 72 jährigen Teilnehmern der SAPALDIA (Swiss cohort study on Air Pollution and 
Lung Diseases in Adults / Schweizer Kohortenstudie Luftverschmutzung und 
Atemwegserkrankungen bei Erwachsenen) Kohorte gemessen. Personen mit einer 
Aufnahmedauer von weniger als 18 Stunden, Vorhofflimmern, Anästhesie in den 
vergangenen acht Tagen, Herzinfarkt oder Digitaliseinnahme wurden ausgeschlossen, damit 
verblieben 1742 Aufzeichnungen. Gesundheitszustand und persönliche Risikofaktoren 
wurden in einem ausführlichen Interview erfragt. Blutdruck, Körpergrösse und Körpergewicht 
sowie Blutwerte (Kreatinin, Harnsäure, hochsensitives C-reaktives Protein, Gesamtchol-
esterin, HDL-Cholesterin und Triglyzeride,) wurden gemessen. Die Auswirkung 
verschiedener Risikofaktoren auf die HRV wurde mit einer strukturierten multivariablen 
linearen Regression geschätzt. Für die Berechnung von geschlechtsabhängigen 
Perzentilenkurven der HRV als Funktion des Alters wurden Personen mit bekannten 
Risikofaktoren (Hypertonie; Rauchen; > 1 Glas alkoholische Getränke pro Tag; 
anamnestisch Diabetes; ACE-Hemmer-, Antiarrhythmika- Klasse I oder III, 
Kalziumantagonisten-, Diuretika- oder Sympathomimetika-Einnahme in den vergangenen 30 
ZUSAMMENFASSUNG   9 
Tagen) ausgeschlossen. Die Auswirkung von Passivrauchexposition auf die HRV, 
Herzfrequenz und den Blutdruck haben wir in multivariablen Regressionsanalysen bestimmt. 
Zur Berechnungen der Auswirkung von körperlicher Aktivität und BMI auf die HRV haben wir 
multivariable Regressionsanalysen verwendet, dabei aber auch Interaktionen zwischen 
diesen Variablen untersucht. 
Resultate: Nach Berücksichtigung des Einflusses des Alters, Lebensstilfaktoren, Variablen 
der kardiovaskulären Gesundheit, Medikamenteneinnahme und kardiovaskulären 
Risikofaktoren im Blut hatten Frauen eine tiefere HRV als Männer. Die altersabhängige 
Abnahme der HRV war unterschiedlich bei Männern und Frauen. Hoher Blutdruck, Rauchen, 
höhere Harnsäurewerte, hoch-sensitives C-reaktives Protein und nicht-HDL-Cholesterin 
hatten unabhängig voneinander einen Zusammenhang mit tieferer HRV. 
Nichtraucher, welche zu Hause oder am Arbeitsplatz für über zwei Stunden pro Tag 
Zigarettenrauch exponiert waren, hatten tiefere HRV-Werte als nicht exponierte Personen. 
Erstere hatten auch eine höhere Herzfrequenz und die Tendenz zu einem höheren 
diastolischen Blutdruck. 
Adipöse, welche sich regelmässig mindestens während zwei Stunden pro Woche körperlich 
betätigen, hatten eine höhere HRV als gleichaltrige ohne körperliche Aktivität. Unabhängig 
vom Gewicht hatten körperlich Aktive die höchste HRV. Auch körperlich aktive Personen mit 
Gewichtszunahme in den vergangenen elf Jahren hatten verglichen mit nicht Aktiven eine 
höhere HRV. Der Einfluss von Adipositas auf die HRV wurde durch regelmässige körperliche 
Aktivität signifikant verändert. 
Schlussfolgerungen: HRV hat einen unabhängigen Zusammenhang mit einer Vielzahl 
bekannter persönlicher und Umweltrisikofaktoren. Unsere Resultate bestätigen, dass 
Passivrauchexposition das kardiale Risiko über autonome Dysfunktion erhöht. Negative 
Effekte von Adipositas auf die HRV können durch regelmässige körperliche Aktivität, welche 
einen starken positiven Einfluss auf die Funktion des autonomen Nervensystems hat, 
vollständig aufgehoben werden. Diese Erkenntnisse können der Forschung bei der 
Interpretation von 24-Stunden-HRV-Werten helfen und sollten Public Health Anstrengungen 
bei der Entwicklung oder Weiterverfolgung von Strategien unterstützen, um die 
kardiovaskuläre Gesundheit zu schützen oder zu verbessern. 
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Abbreviations 
ANS  Autonomic nervous system 
BMI  Body mass index 
CO  Carbon monoxide 
CVD  Cardiovascular disease 
ECG  Electrocardiogram 
ETS  Environmental tobacco smoke 
HDL  High density lipoprotein 
HF  High frequency power 
HRV  Heart rate variability 
hs-CRP High sensitivity C-reactive protein 
LF  Low frequency power 
SAPALDIA Swiss Cohort Study on Air Pollution and Lung Diseases in Adults 
SDNN  Standard deviation of all normal RR intervals 
SOP  Standard operating procedure 
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1. Introduction 
 
1.1 Background 
As the leading cause of mortality in Switzerland (Bundesamt für Statistik 2006) and many 
other developed (Mathers and Loncar 2006; Murray and Lopez 1997) and increasingly 
developing countries (Raymond et al. 2006), cardiovascular disease (CVD) is of high 
significance in public health. In 2003, 41% of women and 35% of men died because of CVD 
in Switzerland (Bundesamt für Statistik 2006). About 30,000 potential years of life (between 
the first and 70th years of life) are lost each year in men and women in Switzerland due to 
CVD (Bundesamt für Statistik 2006). Subjects with CVD have to cope with a lower quality of 
life and often have to live with disablement, an inability to work, and the loss of autonomy 
and mobility. CVD is not only a heavy burden for those who suffer from it, but also for the 
national economy. According to Swiss statistics of medical diagnosis, CVD is the most 
important reason for 13% of all visits to doctor's offices (2001) (Junker 2004) and for 10% of 
hospital stays (2003) (Bundesamt für Statistik 2006). Medications for the treatment of CVD 
were the most commonly sold remedies, taking a market share in Switzerland of 16% (Cueni 
2004). While classical risk factors for CVD have been described in relation to higher 
myocardial infarction or CVD mortality (D'Agostino et al. 2000; Wilson et al. 1998), earlier 
markers of the functioning of the heart and its autonomic control might help to understand 
mechanisms of disease development. This would help to develop earlier and better targeted 
preventive interventions, inasmuch as the evaluation of an individual's risk of experiencing a 
future cardiovascular event. Such evaluations increasingly forms the basis of clinical 
guidelines for prevention of cardiovascular diseases worldwide (Smith et al. 2004). They thus 
might be of importance in epidemiologic and health related research on one hand, but they 
also might be of significance in assessment of the functioning of the heart and hence be a 
useful tool in clinical practice. 
The Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) 
(Ackermann-Liebrich et al. 1997; Leuenberger et al. 2000; Zemp et al. 1999) has measured 
markers of cardiovascular risk in its follow-up study. The study, which was originally 
designed to address the impact of air pollution on respiratory health in Switzerland, examined 
9651 participants in a cross-sectional study in 1991. The participants, then 18 to 60 years 
old, were randomly selected from eight areas of Switzerland representing a broad range of 
environmental and climatic conditions (Aarau, Basel, Davos, Geneva, Lugano, Montana, 
Payerne and Wald) (Martin et al. 1997). Between 2001 and 2003, the second round of health 
examinations of the cohort was accomplished. 8047 participants (83% of the original cohort) 
were reexamined (Ackermann-Liebrich et al. 2005). 
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An extensive health examination was conducted in 1991, including a standardised interview, 
spirometry, methacholine challenge and measurement of endexpiratory carbon monoxide 
(CO) (Martin et al. 1997). These examinations were repeated and in response to new 
scientific evidence, demonstrating a direct effect of elevated air pollutant concentration on 
heart rate (Peters et al. 1999; Pope et al. 1999), heart rate variability (HRV) (Gold et al. 2000; 
Pope et al. 1999), incidence of cardiac arrhythmia (Peters et al. 2000) and on CVD mortality 
(Dockery et al. 1993; Pope 2000; Schwartz 1999), additional assessments were done in the 
second survey, including measurement of cardiovascular risk factors in the blood and of HRV 
(Ackermann-Liebrich et al. 2005). 
While HRV has been used as indicator of cardiovascular health and functioning of the heart, 
literature on HRV in the general population and its influencing factors is relatively scarce. 
This thesis uses a population-based sample of 1742 electrocardiograms (ECG) to describe 
normal values for the Swiss population, personal and environmental risk factors for lowering 
HRV, in addition to showing the effect of physical activity in normal and obese persons. 
 
1.2 Heart rate variability 
Heart rate variability is the temporal variation between sequences of consecutive heartbeats 
(Figures 1 and 2). On a standard ECG, the maximum upwards deflection of a normal QRS 
complex is at the peak of the R wave, and the duration between two adjacent R wave peaks 
is termed the R-R interval. The ECG signal requires editing before HRV analysis can be 
performed, a process requiring the removal of all non-sinus-node-originating beats. The 
resulting period between adjacent QRS complexes resulting from sinus node depolarizations 
is termed the N-N (normal-normal) interval. HRV is the measurement of the variability of the 
N-N intervals (Reed et al. 2005). 
 
Figure 1. Normal ECG trace, with waves labeled 
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Figure 2. Heart rate variability is a measure of the beat-to-beat changes in heart rate 
The cardiovascular concept of homeostasis refers to the tendency of the organism to 
maintain a relatively regular heart rate and blood pressure in the face of changing 
environmental conditions. No physiological variable, however, will give a time sequence that 
is absolutely stationary or periodic. Spontaneous fluctuations can be observed in 
cardiovascular functions, such as heart rate and blood pressure, even when the 
environmental parameters are maintained at as constant a level as possible and no 
perturbing influences can be identified (Makikallio 2000). 
Although automaticity is intrinsic to different cardiac tissues with pacemaker properties, the 
electrical and contractile activity of the myocardium is largely modulated by the autonomic 
nervous system (ANS). This neural regulation is effected through the interplay of the 
sympathetic and vagal outflows. In most physiological conditions the efferent sympathetic 
and parasympathetic branches have opposing actions: the sympathetic system enhances 
automaticity, whereas the parasympathetic system inhibits it. While the effect of vagal 
stimulation on the cardiac pacemaker cells is to cause hyperpolarisation and to reduce the 
rate of depolarization, sympathetic stimulation causes chronotropic effects by increasing the 
rate of pacemaker depolarization. Both branches of the ANS influence ion channel activity 
implicated in the regulation of depolarization of the cardiac pacemaker cells (Sztajzel 2004). 
Vagal mediators exert their influence relatively quickly on the heart, and principally affect the 
high frequency power (HF) of the HRV spectrum (between 0.15 Hz and 0.4 Hz). Sympathetic 
mediators appear to exert their influence over longer time periods and are reflected in the low 
frequency power (LF) (between 0.04 Hz and 0.15 Hz) and the HF power of the HRV 
spectrum. Thus, the LF/HF ratio is a proxy for the sympatho-vagal balance (North American 
Society of Pacing and Electrophysiology 1996). 
Physiological and pathological processes may influence N-N interval variability. Even at rest, 
heart rate fluctuates cyclically. High frequency (HF) cyclic fluctuations are modulated by 
ventilation (respiratory sinus arrhythmia), mediated entirely by changes in vagal outflow. 
Slower fluctuations occur due to baroreflexes or due to thermoregulation. The greatest 
variation of heart rate occurs with circadian changes, particularly the difference between 
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night and day heart rate (Figure 3), mediated by complex and poorly understood 
neurohormonal rhythms. Exercise and emotion also have profound effects on heart rate 
(Kleiger et al. 2005) and thus its variability (see Table 1 for physiological correlation of 
different HRV components). 
 
Figure 3. Changing heart rate over 21 hours 
Respiratory sinus arrhythmia was described by Hales in 1733 (Hales 1733). Although the 
temporal fluctuations in cardiovascular signals were noted in ancient times (Bylebyl 1971), 
physicians have overlooked for a long time the possible significance of beat-to-beat 
fluctuation of cardiovascular signals. This variability has generally been treated as noise to 
be either ignored or averaged out. The field in which the potential clinical significance of 
beat-to-beat variability in cardiovascular signals was first recognised was obstetrics. In 1965, 
the importance of sinus arrhythmia was described in relation to fetal monitoring. This 
variability correlated with fetal viability; diminution of beat-to-beat variability indicated fetal 
compromise (Hon and Lee 1965). In the 1970s, Ewing and colleagues used short-term HRV 
measurements as a marker of diabetic autonomic neuropathy (Ewing et al. 1985). In 1977, 
Wolf and colleagues showed that patients with reduced HRV after a myocardial infarction 
had an increased mortality. This was confirmed by studies showing that HRV is an accurate 
predictor of mortality after myocardial infarction (Bigger et al. 1993; Kleiger et al. 1987; Malik 
et al. 1989). The relative risk of mortality was over five times higher in the group with the 
lowest HRV as compared with the group with the highest HRV (Kleiger et al. 1987). 
In 1981, Akselrod and colleagues introduced power spectral analysis of heart rate 
fluctuations to quantitatively evaluate beat-to-beat cardiovascular control (Akselrod et al. 
1981). 
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Table 1. HRV components and their physiological correlations 
HRV component  spectrum physiological correlation 
SDNNa -------------------- circadian rhythms 
Total Power (TP) < 0.40 Hz --------------------- 
High Frequency (HF) 0.15 – 0.40 Hz vagal activity 
Low Frequency (LF) 0.04 – 0.15 Hz sympathetic and vagal activity, baroreflex 
sensitivity 
LF/HF ratio -------------------- Proposed as balance between sympathetic 
and parasympathetic activities 
Very Low Frequency (VLF) 0.0033 – 0.04 Hz Sympathetic activity + parasympathetic 
activity + thermoregulation + renin-
angiotensin system 
Ultra Low Frequency (ULF) < 0,0033 Hz circadian and neuroendocrine rhythms 
a Standard deviation of all normal-to-normal RR-intervals 
(North American Society of Pacing and Electrophysiology 1996; Sztajzel 2004) 
 
In recent years, alterations in HRV have been found in patients with many conditions: 
Diabetes and high blood pressure have been described as being associated with impaired 
autonomic function (Gerritsen et al. 2001; Kaftan and Kaftan 2000; Singh et al. 1998; Tsuji et 
al. 1996); history of myocardial infarction or congestive heart failure is also associated with 
lower values of HRV (Casolo et al. 1989; Tsuji et al. 1996); obstructive sleep apnea 
syndrome (Roche et al. 1999), chronic renal failure (Kurata et al. 2000), depression in 
patients with stable coronary heart disease (Stein et al. 2000) and even tinnitus (Datzov et al. 
1999) showed an association with HRV in various studies. HRV has also been extensively 
investigated as a tool to predict death and nonfatal cardiovascular events both in survivors of 
myocardial infarction (Bigger et al. 1993; Kleiger et al. 1987; Tapanainen et al. 2002) and in 
the asymptomatic population (Tsuji et al. 1994). Pozzati and colleagues showed that HRV 
decreased significantly in the five minutes before dying in patients with sudden ischemic 
death during Holter monitoring (Pozzati et al. 1995). 
From a functional perspective, the ANS not only includes efferent, but also afferent pathways 
transmitting information regarding the heart. HRV is therefore also dependent on the state of 
the heart. It has been shown that HRV is associated with ventricular ejection fraction and it 
also appears to be related to the size of acute myocardial infarction. It is inversely related to 
peak myocardial-type creatine kinase (CK-MB) (Odemuyiwa 1995). 
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Despite all the research done in this field, little is known about 24-hour HRV in a normal 
population. HRV offers prognostic information independent of and beyond that provided by 
traditional risk factors. The Task Force of the European Society of Cardiology and the North 
American Society for Pacing and Electrophysiology stated in 1996 that large population-
based studies are needed to establish normal HRV standards for various age and sex 
subsets (North American Society of Pacing and Electrophysiology 1996). To our knowledge, 
studies measuring 24-hour HRV in a normal population published since then included up to 
300 subjects (Ramaekers et al. 1998; Sosnowski et al. 2002; Umetani et al. 1998), but most 
studies were restricted to short-term measurements. To date, no such reference values for 
Switzerland have been published. 
HRV is known to be influenced by a great variety of factors, like age, sex, or medication 
intake. The association between single or combined factors and HRV has been explored in 
numerous patient studies. To our knowledge, no results about the combined effect of such a 
wide range of risk factors on HRV in a large population sample have been published yet. 
Understanding of the risk factors for cardiovascular disease may yield important insights into 
the prevention, etiology, course, and treatment of this major public health concern. Exposure 
to environmental factors such as tobacco smoke pollution is known to be a risk factor for 
cardiovascular disease. To date, the association between longer-term exposure to 
environmental tobacco smoke (ETS) and HRV, heart rate, or blood pressure, the alterations 
of which could potentially be steps in the pathophysiological pathway leading from ETS 
exposure to cardiopulmonary disease, has not been analysed. 
Sedentary lifestyle and obesity are also both well-established risk factors for cardiovascular 
disease. Different studies have shown an association of either of them with lower HRV. 
However, it is not known whether the unfavourable effects of obesity would be modified by 
regular physical activity. 
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1.3 Aims 
The overall aim of this thesis was to study heart rate variability, which is a predictor of 
death and nonfatal cardiovascular events, and its determining factors. 
 
In particular, the following research questions were addressed: 
 
1. What is the normal heart rate variability in a general elderly Swiss population and what 
are its determinants (personal risk factors?) 
 
Specific aims: 
I. To determine the influence of cardiovascular risk factors, biomarkers for 
cardiovascular health and current health status on heart rate variability. 
II. To provide normal ageing curves for healthy men and women between 50 and 
70 years of age living in Switzerland for various HRV measurements. 
 
 
2. What is the influence of environmental risk factors on heart rate variability, using 
exposure to environmental tobacco smoke as an example? 
 
Specific aims: 
I. To test the hypothesis that longer-term exposure to environmental tobacco 
smoke reduces heart rate variability in the general population. 
II. To discuss possible pathways towards reduced HRV 
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3. Is there a modification of the negative effect of obesity on heart rate variability by 
physical activity?  
 
Specific aims: 
I. To test the hypothesis that regular exercise improves heart rate variability. 
II. To determine whether adverse effects of obesity and weight gain on heart rate 
variability would be modified by regular exercise. 
 
 
In the three papers presented in this thesis, we specifically analysed HRV and its 
determinants in a healthy population and present normal values for the Swiss population. As 
an example of an environmental risk factor, we studied the influence of passive smoking on 
HRV. The impact of obesity and sedentary lifestyle as personal risk factors on HRV and the 
possibility of enhancing HRV by regular exercise are elucidated in the third paper. 
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1.4 Methods 
 
SAPALDIA had its baseline assessment in 1991. In 2001-2003, we specifically looked at 
cardiovascular health. The participants of this study were a random selection of the 4417 
SAPALDIA 2 subjects aged ≥ 50. A total of 1846 subjects (955 women, 891 men) took part in 
the HRV measurements. They underwent 24-hour ECG recordings and filled in a time activity 
diary. Blood pressure, height and weight as well as cardiovascular risk factors in the blood 
were measured. Information about cardiovascular risk factors was obtained in an extensive 
interview. The subsequent chapter describes details of HRV and blood pressure 
measurements. More information about inclusion criteria, HRV and other measurements and 
analyses are given in chapters two through four. 
24-hour electrocardiogram 
24-hour ECG recordings were conducted with digital Holter recorders (Aria, Del Mar Medical 
Systems, Irvine, CA, USA), using three leads. The placement of the electrodes for V3 and V5 
was altered, thus resulting in higher R-waves which are desirable for reading HRV. The 
electrodes for V1 were customarily placed. After site visits in laboratories in Rochester (USA), 
Erfurt (Germany) and Saint-Etienne (France), where epidemiological studies of HRV were 
performed, a standard operating procedure (SOP) was developed (see appendix 1). It was 
tested in a pilot study with 30 volunteers, where the practicability of the SOP for the field 
workers, of the instructions for the persons being tested and of their compliance were 
analysed. The reliability of the devices, the quality of the recordings and the functioning of 
data transfer were also tested. Part of the pilot study was a double ECG recording in 10 
participants, where in two simultaneous ECG recordings the electrodes where placed in 
slightly different places (results shown in appendix 3). In the pilot study, a time activity diary 
was also tested, which was adapted for the use of SAPALDIA from the time activity diary of 
the EXPOLIS study (see appendix 5) (Rotko et al. 2000). A smoothly running logistic was 
developed during this test period, which included the returning of the devices by the 
participants by mail, downloading the data from the ECG recorders to a local hard disc and 
copying the data from there to a compact disc, sending the disc to the coordinating centre 
and from there to the laboratory in France where the ECGs were analysed. In case of a 
dangerous condition spotted on the ECG, the coordinating centre and thereby the 
responsible study physician was notified immediately. The concerning participant was then 
contacted via telephone by the study physician, who offered to inform the subject's family 
physician. The results of normal ECGs were sent back from the laboratory to the 
coordinating centre and were distributed from there to the local centres. Participants then 
received their report from the local centres in writing if requested. This procedure allowed the 
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recording of 1846 ECGs using 26 devices. Participants without pathologies received a 
feedback within approximately four to six weeks. 
There were 32 fieldworkers working in the eight SAPALDIA study centres. They were all 
intensively trained and supervised in order to guarantee a standardized examination of the 
subjects. 
 
Reading and analyses of electrocardiograms 
The ECGs recorded using the Holter recorders were analysed at the laboratory of Dr. 
Barthélemy at the Université de St. Etienne (Roche et al. 2002; Roche et al. 1999) with 
programs especially developed for this study (details in appendix 2). 
Variability was assessed using time and frequency domain analysis that quantify periodicities 
in the data captured by a monitor. Standard variables relating to the Holter recording, and 
two sets of variables for heart rate variability (Fast Fourier transformation and wavelet 
transformation) were calculated (Pichot et al. 1999). Variables in the analysis include 18 
items for heart rate variability for the periods of day and night and the entire recording period 
for each subject. Recording time, duration of artefacts, frequencies (minimum, mean, and 
maximum), arrhythmias (number, duration, minimal frequency of bradycardia, number, 
duration and time of pauses, number, frequency and type of ventricular premature beats 
including accelerated idioventricular rhythms and ventricular tachycardia, number, frequency 
and type of supraventricular tachycardia including paroxysmal supraventricular tachycardia) 
and changes in ST (type, number, lead) were also been measured. Tables 2 and 3 
summarize the available time domaine and frequency domaine variables. 
Reliability of HRV analyses was tested by analyzing 30 ECG recordings twice with the Holter 
technician being blindfolded (results shown in appendix 4). 
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Table 2. HRV time domain parameters 
Time domain parameters entire recording day night 
Mean RR [ms] x x x 
NN50 x x x 
pNN50 [%] x x x 
SDNN [ms] x x x 
RMSSD [ms] x x x 
SDANN [ms] x x x 
SDNN index [ms] x x x 
HRV triangular index x x x 
TINN [ms] x x x 
 
Table 3. HRV frequency domain parameters 
frequency domain parameters frequency entire recording day night 
  FT WT FT WT FT WT 
Total Power [ms2] < 0,40 Hz x x x x x x 
ULF [ms2] < 0,0033 Hz x x     
VLF [ms2] 0,0033 – 0,04 Hz x x x x x x 
LF [ms2] 0,04 – 0,15 Hz x x x x x x 
HF [ms2] 0,15 – 0,40 Hz x x x x x x 
Alpha  x      
LF (normalized units)    x x x x 
HF (normalized units)    x x x x 
LF/HF    x x x x 
FT: Fourier transform, WT: Wavelet transform 
 
Measurement of blood pressure 
Blood pressure was measured twice with participants at rest and sitting by an automatic 
device (705CP, OMRON, Tokyo, Japan), which has been tested in two studies and was 
recommended using the criteria of the British Hypertension Society (BHS) and the US 
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Association for the Advancement of Medical Instrumentation (Artigao et al. 2000; O'Brien et 
al. 1996). The devices were tested before their use and shortly before the end of the study 
according to the statements of conformity EN 1060-1, 1060-2 and 1060-3 (harmonized 
according to the European Union Medical Device Directive 93/42/EEC) (European Union 
1999; European Union 2002). Measurement of blood pressure followed the 
recommendations of the WHO (see annex 1) (World Health Organization 1994). 
 
The original contribution of the author concerning the methods consisted in the development 
of the standard operating procedures for the Holter recording and blood pressure 
measurement for the purposes of SAPALDIA 2 and the training and supervision of the 
fieldworkers in regular quality control sessions. Statistical analyses presented in this thesis 
were conducted by the author. 
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2. Paper 1: Reference values and determining factors of heart rate 
variability 
2.1 Heart rate variability in an ageing population and its association with 
lifestyle and cardiovascular risk factors: results of the SAPALDIA study 
 
 
 
Additional percentile curves are shown in appendix 6. 
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Aims (i) To report associations between cardiovascular risk factors and heart rate variability (HRV) in a
general population and (ii) to provide normal values for various HRV measurements in a healthy
European general population sample aged 50.
Methods and results Twenty-four-hour electrocardiograms were recorded in 1742 randomly selected
SAPALDIA (Swiss cohort study on Air Pollution and Lung Diseases in Adults) participants aged 50. In
multivariate regression analyses, women (n ¼ 895) had a 6.1% lower standard deviation of all normal
RR (NN) intervals (SDNN), a 11.4% lower total power (TP), and a 27.2% lower low-frequency (LF)
power than men (n ¼ 847). Per unit increase in BMI, SDNN decreased by 0.7% and TP decreased by
1.2%. Persons with high blood pressure had a 9.2% lower LF than normotensive persons and current
smokers a 15.5% lower LF than never smokers. Each hour of heavy physical exercise was associated
with a 2.0% increase in SDNN, a 3.6% increase in the high frequency (HF) range power and a 4.2% increase
in LF power. Higher levels of uric acid, high-sensitive C-reactive protein and non-HDL-cholesterol were
associated with lower TP, HF and LF. Percentiles of TP and LF/HF as a function of age were calculated
for an asymptomatic subsample of participants (n ¼ 499) free of cardioactive medications.
Conclusion Heart rate variability in a general population sample shows expected associations with all
known cardiovascular risk factors, although not identically for all HRV domains. Together with our percen-
tile estimates for HRV as a function of age, these findings could assist scientists in interpreting 24 h HRV
values and factors influencing them in an ageing population.
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Introduction
Heart rate variability (HRV), a measure of cardiac autonomic
control (see Table 1 for physiological correlations of diffe-
rent HRV components), has been established as a strong pre-
dictor of death and non-fatal cardiovascular events both in
survivors of a myocardial infarction1–3 and in an asympto-
matic population. The Framingham Study has found that
reduced HRV in short-term recordings (2 h) predicted new
cardiac events, hypertension and hyperglycaemia, in a
middle-aged general population,4–6 and the Whitehall
Study showed associations between social position, beha-
vioural factors, components of the metabolic syndrome,
and HRV.7 However, little is known about 24 h HRV in a
normal population.8 The Task Force of the European
Society of Cardiology and the North American Society for
Pacing and Electrophysiology have identified the need for
large prospective population studies to establish normal
HRV standards for various age and sex categories.9
& The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
* Corresponding author. Tel: þ41 61 267 60 66; fax: þ41 61 267 61 90.
E-mail address: denise.felber@unibas.ch
Europace (2006) 8, 521–529
doi:10.1093/europace/eul063
The SAPALDIA (Swiss Cohort Study on Air Pollution and
Lung Diseases in Adults) cohort was designed to measure
the health effects from long-term exposure to air pollutants
in the Swiss adult population.10,11 In 1991, a random sample
of the Swiss population was recruited from eight areas fea-
turing distinct geographical and environmental conditions.
In a follow-up examination in 2002, 24 h measurements of
HRV were included in those aged 50.
In this paper we (i) report the cross-sectional associations
of cardiovascular risk factors and cardiovascular disease
with HRV in the full sample and (ii) provide normative
values for total power and the low to high frequency ratio
in a healthy subsample of a large European population
aged 50. Normal curves for other HRV parameters are
available from the authors on request.
Methods
Participants
The design and objectives of the SAPALDIA cohort study have been
reported in detail elsewhere.12 In brief, 9651 participants received
intensive health examinations and a detailed health interview in
1991 and have been followed since then. In 2002, we were able to
re-examine 8047 of the original participants. A random selection
of the 4417 participants aged 50 were invited to participate in
the HRV assessment and a total of 1846 subjects (955 women, 891
men) participated.
Exclusion criteria were general or spinal anaesthesia in 8 days
prior to the ambulatory ECG recording (n ¼ 5), having had a myocar-
dial infarction in 3 months prior to the exam (n ¼ 2), and taking digi-
talis (n ¼ 6); nobody had an artificial pacemaker. After exclusion of
recordings showing atrial fibrillation (n ¼ 12), recordings of ,18 h
(recommendations of the Task Force of the European Society of
Cardiology and the North American Society of Pacing and
Electrophysiology9) (n ¼ 73), and 6 recordings of insufficient
quality, 1742 subjects were included in this analysis assessing the
cross-sectional associations of cardiovascular risk factors or cardio-
vascular diseases with different parameters of HRV.
HRV measurements and analyses
For the Holter recording, digital devices (Aria, Del Mar Medical
Systems, Irvine, CA, USA) with a frequency response of 0.05–40 Hz
and a resolution of 128 samples/s were used. Three leads (V1,
altered V3 with the electrode on the left midclavicular line on the
lowest rib, and altered V5 with the electrode on the left anterior
axillary line on the lowest rib) were recorded over 24 h. The mean
duration of the Holter recordings was 22.3 (SD 2.1) h.
All recordings were scanned through a StrataScan 563 (Del Mar)
and interpreted using the interactive method, with a final visual
check on the full disclosure. The length of each RR interval was
manually validated during this step. Resampling was made at
4 Hz. Spectral analysis was performed by the fast Fourier transform
method using sliding 256 polynomial time approximation scheme
(PTAs) windows for day and night periods. For 24 h periods, calcu-
lations of RR intervals were made without a sliding window, to
allow measurement of ultra-low frequency (ULF) and very low fre-
quency (VLF). Only normal-to-normal intervals were used, with
intervals excluded due to ectopy or artefacts being replaced by
holding the previous coupling interval level throughout the time
interval to the next valid coupling interval. The standard deviation
of all normal RR (NN) intervals (SDNN) and the following frequency
domain variables have been calculated: Total power (TP) (0.40 Hz),
ULF power (0.0033 Hz), VLF power (0.0033–0.04 Hz), LF power
(0.04–0.15 Hz), high frequency (HF) power (0.15–0.40 Hz), and the
ratio between LF and HF (LF/HF).
In order to avoid a biased result due to methacholine challenge,
which was part of the SAPALDIA lung function testing and which,
for practical reasons, was performed before the Holter recording,
we excluded the first 2 h of all recordings.
The Holter recordings were made between August 2001 and March
2003. The recorders were placed on participants after a detailed
health interview to those giving consent. Participants were asked
to follow their regular daily routine and to complete a time-activity
diary during the recording period.
Interview
During the interview, information about smoking habits (Questions:
‘Have you ever smoked for as long as a year?’ ‘Do you now smoke, as
of 1 month ago?’ ‘Have you stopped or cut down smoking?’), recent
myocardial infarction (‘Did you have a myocardial infarction in the
past 3 months?’), comorbidities (‘Do you have any of the following
conditions: . . ., hypertension,. . ., diabetes,. . . ?’), drinking habits
(‘How often do you normally drink alcoholic beverages like beer,
wine, liqueurs, aperitifs, and strong drinks?’ ‘How often do you nor-
mally drink a glass of red wine?’), and amount of physical exercise
(‘We are talking about physical exercise where you get out of
breath at least a little bit, like fast walking, hiking, dancing,
gardening, or a variety of sports. On how many days of the week
do you do such exercises? On average, how many minutes per day
do you do such exercises?’ ‘How many hours a week do you
usually exercise such that you get out of breath or sweat?’) had
been obtained. Participants were asked to bring all their drugs to
the study centre in order to complete a medication list.
Other measurements
Serum creatinine, uric acid, total cholesterol, high density lipo-
protein (HDL) cholesterol, triglycerides, and high sensitivity (hs)
Table 1 HRV components and their physiological correlations
HRV
component
Spectrum Physiological correlation
SDNN — Circadian rhythms
TP 0.40 Hz —
HF 0.15–0.40 Hz Vagal activity
LF 0.04–0.15 Hz Sympathetic and vagal activity, baroreflex sensitivity
LF/HF ratio — Proposed as balance between sympathetic and parasympathetic activities
VLF 0.0033–0.04 Hz Sympathetic activityþ parasympathetic activityþ thermoregulationþ
renin–angiotensin system
ULF ,0.0033 Hz Circadian and neuroendocrine rhythms
From the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology9 and
Sztajzel.49
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C-reactive protein (CRP) were measured in the blood as known
cardiovascular risk factors. High density lipoprotein values could
only be obtained if the participants had a triglyceride level of
9.4 mmol/L. Normal values for uric acid were 210–420 mmol/L for
men and 150–350 mmol/L for women, for hs-CRP protein RP (should
say: hs-CRP) ,5.0 mg/L, for total cholesterol ,5.0 mmol/L, and for
HDL.1.0 mmol/L in both men and women8. Low density lipoprotein
levels were calculated using the formula of Friedewald for subjects
who had fasted for at least 6 h and had triglyceride levels of
4.7 mmol/L. As a further atherogenic marker, the difference
between total cholesterol and HDL (non-HDL-cholesterol) was calcu-
lated, as well as the quotient between total cholesterol and HDL.
Blood pressure was measured twice with participants at rest and
sitting by an automatic device (705CP, OMRON, Tokyo, Japan) posi-
tioned on the left upper arm according to WHO recommendations.13
Blood pressure values used in the regression models were the arith-
metic mean of the two measurements.
High blood pressure was defined as either having a systolic blood
pressure 140 mmHg and/or a diastolic blood pressure 90 mmHg
and/or having answered yes to the question ‘Do you have
hypertension?’
Body height and weight were measured with the participant not
wearing any shoes or coat. End-expiratory carbon monoxide (CO) was
measured using an EC50 Micro-Smokerlyzer (BEDFONT, Rochester, UK).
This protocol was approved by the Ethics Committee of the Swiss
Academy of Medical Sciences and the responsible Cantonal Ethics
Committees.
Statistical analysis
Statistical analysis was performed using the software packages
STATA 8.0 (Stata corporation, College Station, TX, USA) and SAS
Vers. 8.2 (The SAS System, Cary, NC, USA).
To assess sex differences, in Tables 2–4, x2 tests (for proportions)
and t-tests (for means) were used. For comparison of the mean
values across different age groups, one-way ANOVA was performed.
Because the distribution of the HRV values was skewed, values
were log-transformed before analysis.
Table 2 Baseline characteristics of the total study population
Men Women All
Sex 847 (48.6%) 895 (52.4%) 1742
Age (years) 60.3 (SD 6.1) 60.4 (SD 6.4) 60.4 (SD 6.3)
Lifestyle factors
Never smokers 277 (32.7%) 522 (58.5%) 799 (45.9%)
Former smokers 376 (44.4%) 227 (25.4%) 603 (34.7%)
Current smokers 193 (22.8%) 144 (16.1%) 337 (19.4%)
CO (ppm) 5.6 (SD 9.6) 4.3 (SD 7.6) 4.9 (SD 8.7)
Alcohola,b
,1 glass/day 499 (59.3%) 728 (81.7%) 1227 (70.8%)
1 glass/day 343 (40.7%) 163 (18.3%) 506 (29.2%)
Red winea
,1 glass/week 318 (37.8%) 589 (66.1%) 907 (52.3%)
1 glass/week 524 (62.2%) 302 (33.9%) 826 (47.7%)
Light physical activitya
22 days/week 443 (52.7%) 438 (49.2%) 881 (50.9%)
.2 days/week 397 (47.3%) 452 (50.8%) 849 (49.1%)
Heavy physical acitivitya
1 h/week 575 (68.8%) 713 (80.5%) 1288 (74.8%)
.1 h/week 261 (31.2%) 173 (19.5%) 434 (25.2%)
Cardiovascular health
SBP (mmHg) 137.2 (SD 19.1) 127.2 (SD 18.6) 132.1 (SD 19.5)
DBP (mmHg) 84.3 (SD 10.5) 79.0 (SD 10.2) 81.6 (SD 10.7)
Self-reported diabetes 44 (5.2%) 30 (3.4%) 74 (4.3%)
BMIc (kg/m2) 27.1 (SD 3.5) 26.3 (SD 4.9) 26.7 (SD 4.3)
Medication
ACE-inhibitor 53 (6.3%) 57 (6.4%) 110 (6.3%)
Antiarrhythmic drugs class I and III 5 (0.6%) 2 (0.2%) 7 (0.4%)
Beta-blockers 99 (11.7%) 93 (10.4%) 192 (11.0%)
Calcium channel blockers 43 (5.1%) 38 (4.2%) 81 4.6%
Diuretics 20 (2.4%) 42 (4.7%) 62 3.6%
Sympathomimetics 31 (3.7%) 26 (2.9%) 57 3.3%
Laboratory parameters
Uric acid (mmol/L) 367.5 (SD 78.8) 284.6 (SD 70.1) 325.1 (SD 85.2)
hs-C-reactive protein (mg/L) 2.6 (SD 6.3) 2.5 (SD 3.7) 2.6 (SD 5.2)
Non-HDL-cholesterold (mmol/L) 4.8 (SD 1.1) 4.7 (SD 1.1) 4.8 (SD 1.1)
SBP, systolic blood pressure; DBP, diastolic blood pressure.
aMore categories have been used in the regression analysis.
bAlcoholic beverages including red wine.
cBMI ¼ body weight/body height2.
dTotal cholesterol2 HDL-cholesterol.
P , 0.05 (differences between sexes).
P , 0.01 (differences between sexes).
P, 0.001 (differences between sexes).
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To assess associations of different risk factors with HRV
measurements, a structured multivariable linear regression was per-
formed. Because of the known association of HRV with age and sex,
these variables were a priori included in the model.14 Variables
were then examined by categories (cardiovascular health, alcohol
intake, smoking, medication, exercise, laboratory results). Within
each category, multiple variables were considered simultaneously,
and backwards elimination was used to choose the best predictors
of HRV from candidate variables. After the most important
representatives of each category of covariates were combined in a
full model, backward selection was used in order to identify covari-
ates that might have lost their importance in the multivariable
setting. In the final model, all baseline characteristics reported in
Table 2, as well as dummy variables for the study areas, were
included.
Calculation of percentiles
For calculating percentiles of HRV, a ‘healthy’ subsample of the
sample described so far was defined by requiring the absence of
each of the following conditions: high blood pressure (systolic
blood pressure 140 mmHg or diastolic blood pressure
90 mmHg), current smoking, alcohol consumption of more than
one glass per day, self-reported diabetes, intake of ACE-inhibitors,
antiarrhythmic drugs classes I and III, calcium channel blockers,
diuretics, or sympathomimetics in the preceding 30 days. Three
hundred and twenty-nine women and 170 men fulfilled these cri-
teria and could be included in the definition of ‘healthy individuals’.
Percentiles of power as a function of age in a healthy population
have been estimated in the following way: for each of the probabil-
ities P ¼ 0.05, 0.25, 0.5, 0.75, 0.95, the p-quantile of ln(TP) for a
given age x was assumed to be of the form yp(x) ¼ b0þ b1zpþ b2x þ
b3zpxþ b4x2þ b5zpx2, where zp denotes the p-quantile of the
standard normal distribution.
This implies that, for each age x, the distribution of ln(TP) is
normal with mean b0þ b2xþ b4x2 and standard deviation
b1þ b3xþ b5x2. Exploration of the residuals of ln(TP) after
regression against age and square of the age indicated that this
assumption was tenable. The six parameters of this equation were
estimated using weighted L1-regression. Details of this method
are given in Braendli et al.15 and Koenker and Basset.16
Results
Table 2 gives an overview of the study population’s baseline
characteristics. Although there were slightly more women
than men, their mean age was identical. Men more
frequently had an unhealthy lifestyle (smoking, alcohol
drinking), more often were overweight and had on average
Table 3 Unadjusted meana HRV values for men and women of different age groups of the total study population
Age (years)
Sex 50–54
(nm ¼ 181; nf ¼ 219)
55–59
(nm ¼ 238; nf ¼ 217)
60–64
(nm ¼ 186; nf ¼ 189)
65–73
(nm ¼ 242; nf ¼ 270)
SDNN (ms) Men 138.2 129.2 130.8 131.9
(95% CI) (132.5–144.1) (124.8–133.8) (126.0–135.7) (127.0–137.1)
Women 135.8 134.7 130.6 123.6
(95% CI) (131.0–140.7) (130.4–139.2) (126.2–135.3) (119.5–127.9)
TP (ms2) Men 3925.2 3616.1 3597.3 3585.8
(95% CI) (3568.6–4317.4) (3340.5–3914.5) (3295.8–3926.5) (3288.4–3910.1)
Women 4134.0 3876.5 3514.6 3200.5
(95% CI) (3818.3–4475.8) (3600.2–4174.1) (3223.4–3832.1) (2973.4–3445.0)
HF (ms2) Men 63.6 59.7 61.0 68.0
(95% CI) (55.4–72.9) (53.0–67.2) (53.4–69.7) (59.4–77.8)
Women 87.8 81.0 66.1 65.3
(95% CI) (79.1–97.4) (72.6–90.4) (57.6–75.7) (58.6–72.8)
LF (ms2) Men 318.1 260.7 228.4 196.0
(95% CI) (284.4–355.8) (237.9–285.7) (205.9–253.4) (175.7–218.5)
Women 258.2 234.9 179.0 147.7
(95% CI) (238.0–280.0) (214.5–257.3) (161.0–199.0) (135.1–161.4)
LF/HF Men 5.0 4.4 3.7 2.9
(95% CI) (4.6–5.4) (4.1–4.7) (3.4–4.1) (2.6–3.2)
Women 2.9 2.9 2.7 2.3
(95% CI) (2.7–3.2) (2.7–3.1) (2.5–3.0) (2.1–2.4)
VLF (ms2) Men 719.1 641.7 637.9 563.0
(95% CI) (650.3–795.3) (589.6–698.3) (581.0–700.5) (511.2–620.1)
Women 668.5 623.7 504.3 450.0
(95% CI) (621.6–719.0) (575.6–675.8) (461.9–550.6) (418.7–483.6)
ULF (ms2) Men 2653.7 2479.2 2463.4 2515.2
(95% CI) (2390.7–2945.5) (2273.1–2704.0) (2232.5–2718.1) (2293.2–2758.7)
Women 2928.7 2790.5 2605.8 2384.8
(95% CI) (2674.4–3207.1) (2578.7–3019.8) (2375.1–2858.8) (2200.5–2584.6)
nm, number of male participants; nf, number of female participants.
aGeometric means are shown because values were skewed.
P, 0.05 (differences between sexes).
P, 0.01 (differences between sexes).
P , 0.001 (differences between sexes).
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a higher blood pressure, but more frequently reported heavy
physical exercise. Medication intake was similar for both
sexes, except for diuretics which were taken twice as
often by women. A surprisingly high proportion (11%) of par-
ticipants were taking beta-blockers; 18.6% of the subjects
were on at least one and 5.0% on more than one of the
drugs listed in Table 2.
Table 3 shows the unadjusted geometric means of HRV
values for the 1742 men and women in different age
groups. Men of all combined age groups had significantly
lower HF than women, but higher LF, LF/HF, and VLF.
Looking at each age group separately, women of the oldest
age group (65–73 years) had significantly lower SDNN, TP,
LF, LF/HF, and VLF than men of the same age group.
Across all age groups, women had significantly lower
average LF/HF ratios than men, but women between 50
and 59 years had higher HF than men of their age.
Table 4 shows covariate-adjusted estimates of the per
cent changes of frequency domain variables of HRV associ-
ated with different lifestyle or risk factors.
Even after adjustment for all other factors, women had
significantly lower values for all HRV parameters, except
for HF and ULF. TP, for example, was 11.4% lower in
women than in men. All HRV parameters except ULF
decreased with age in both sexes. HF decreased 1.4% per
year and LF 3.2% (Table 4, first two rows).
Lifestyle factors
Although former smoking showed no influence, we found
current smoking to be the strongest predictor for HRV with
a decrease mainly in sympathetic activity (SDNN 24.5%,
TP 215.0%, LF 215.5%, VLF 216.6%, and ULF 214.9%).
Independent of being a current smoker, CO in exhaled air,
as a measure of recent tobacco smoke exposure, showed a
significant association with decreased SDNN (20.3%), LF
(20.6%), LF/HF (20.6%), and VLF (20.6%). The consump-
tion of one glass of alcoholic beverage per day showed a
significant association with decreased TP (215.7%), LF
(219.0%), and VLF (217.7%). Heavy physical exercise was
generally associated with higher HRV: SDNN, TP, HF, LF,
VLF, and ULF increased significantly by 2.0% per weekly
hour of heavy exercise.
Cardiovascular health
Having high blood pressure as defined above primarily
affected sympathetic tone, with decreases in TP, LF, VLF,
and ULF, whereas a higher body mass index (BMI) was associ-
ated with a decrease in all HRV parameters except HF. On
average, TP decreased by 1.2% for each additional kg/m2 of
BMI. Self-reported diabetes decreased ULF significantly by
16.5%.
Table 4 Adjusted estimatesa of mean per cent changes of HRV associated with different risk factorsb
SDNN (%) TP (%) HF (%) LF (%) LF/HF (%) VLF (%) ULF (%)
Female sex 26.1 211.4 6.0 227.2 231.3  223.1 26.3
Age (year) 20.3 20.9 21.4 23.2 21.9 21.9 20.5
Lifestyle factors
Former vs. never smoking 21.8 21.7 6.6 4.7 21.8 20.1 23.3
Current vs. never smoking 24.5 215.0 210.5 215.5 25.6 216.6 214.9
CO (ppm) 20.3 20.3 0.0 20.6 20.6 20.6 20.3
,1 glass alcohol/day vs. 0 21.0 26.0 25.7 28.8 23.3 28.1 25.8
1 glass alcohol/day vs. 0 23.0 215.7 219.2 219.0 0.3 217.7 213.7
.1 glass alcohol/day vs. 0 22.0 213.5 211.0 214.6 24.0 211.6 214.6
Exercise heavy vs. never 2.0 3.4 3.6 4.2 0.6 4.1 3.2
Cardiovascular health
High BPc 21.3 27.1 25.4 29.2 24.0 26.9 27.5
Self-reported diabetes 26.7 214.2 25.4 216.1 211.3 214.8 216.5
BMI (kg/m2)d 20.7 21.2 0.5 21.0 21.5 21.2 21.1
Medications
ACE-inhibitors 4.1 17.3 19.1 13.7 24.5 14.0 16.5
Antiarrhythmics 13.2 20.3 206.7 13.4 263.0 27.6 2.5
Beta-blockers 26.9 12.3 21.5 7.1 211.9 24.2 10.5
Ca blockers 20.6 21.6 20.7 22.2 219.0 24.0 21.8
Diuretics 23.3 219.9 216.0 225.2 211.0 227.1 221.4
Sympathomimetics 21.6 211.9 212.6 212.7 20.1 210.0 210.8
Laboratory parameters
Uric acid (mmol/L) 0.0 20.1 20.1 20.1 0.0 20.1 20.1
hs-C-reactive protein (mg/L) 20.4 21.0 21.1 21.7 20.6 21.5 20.8
Non-HDL-cholesterol (mmol/L)e 20.2 22.8 27.5 23.7 4.0 23.1 22.2
aDerived from regression model including all factors in Table 2 and study site.
bEffect estimates for quantitative covariates refer to one unit increments in these variables. The respective units are given in parentheses.
cHigh blood pressure ¼ systolic blood pressure 140 mmHg or diastolic blood pressure .90 mmHg or self-reported high blood pressure.
dBMI ¼ body weight/body height2.
eTotal cholesterol2 HDL-cholesterol.
P , 0.05.
P , 0.01.
P, 0.001.
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Medications
Among the drugs examined, antiarrhythmics, as expected,
showed the strongest association with HRV, followed by
diuretics and beta-blockers. Persons taking diuretics
showed significantly diminished TP, LF, VLF, and ULF.
Subjects on beta-blockers had an increased vagal tone,
with increases in TP of 13%, HF of 22%, and VLF of 25%,
but with a 12% decrease in LF/HF. Subjects on ACE-inhibitors
had a 18% increase in TP.
Laboratory parameters
All laboratory parameters of the regression model (uric acid,
hs-CRP, and non-HDL-cholesterol) consistently showed nega-
tive associations with most HRV parameters. The exceptions
were the LF/HF ratio for uric acid and SDNN as well as ULF
for non-HDL-cholesterol. Both HF and LF decreased by
0.1%/mmol/L increase in uric acid. Per unit increase in
hs-CRP, HF decreased by 1.1% and LF by 1.7%. Non-HDL-
cholesterol showed a highly significant association with
decreased vagal and sympathetic tone (with decreases in
HF and LF by 7.5 and 3.7%, respectively).
Normal values
It is often useful to compare subjects or patients’ HRV with
that found in age- and sex-matched healthy populations. To
construct such normal ageing curves for men and women
between 50 and 70 years of age, we chose all non-smoking
individuals without history of cardiovascular disease, high
blood pressure or diabetes, and free of medications, as
described in Methods. We then calculated normal ageing
curves, which are shown in Figures 1 and 2.
In men, LF/HF values clearly decrease between 50 and 70
years of age. In women, such a decrease is only observed
after age 60.
Discussion
In this study, we have analysed different factors influencing
HRV in a population-based sample aged 50–72. We are not
aware of many studies about the respective importance of
different predictors of HRV, although HRV is known to be
influenced by a great variety of factors.8 Because of our
relatively large sample size, we were also able to
estimate age-dependent percentile curves for normotensive
non-smoking subjects aged 50 without cardioactive drug
intake or moderate to high alcohol consumption. As a
result, we are able to show different ageing patterns for
HRV in men and women. We found TP to decline clearly
with age in men, whereas HF showed this pattern in
women. This results in an earlier and more marked
age-related decline of LF/HF ratio in men than in women,
consistent with the higher life expectancy and the lower
risk for cardiovascular diseases of women. This difference
might explain why not all previous studies found an
age-related decrease in HRV. Age has been described to be
negatively associated with frequency domain measures,17–21
which represent both vagal and sympathetic activity. Some
authors19 found this association only in men. Other authors
found a negative association with frequency domain vari-
ables in the female sex,17,18,22 whereas Stein et al.19
describe this association only in subgroups. As stated by
Parati and Di Rienzo,14 age and gender should always be
taken into account when quantifying HRV.
Inconsistent findings concerning the effect of smoking on
HRV have been reported in the literature.23,24 In our study,
we found both a strong effect of smoking and an indepen-
dent association with end expiratory CO levels. Although
nicotine is a stimulant of the sympathetic nervous system,
we found a significant reduction of LF in current smokers.
This suggests that either the toxic effect of other com-
ponents of tobacco smoke is stronger than the increase in
the sympathetic tone expected from nicotine alone,
leading to an accelerated ageing of the heart, or the con-
tinuous stimulation of the sympathetic nervous system even-
tually leads to the weakening of the response. In the context
of all the risk factors considered, we also found an indepen-
dent negative effect of alcohol consumption on HRV, which
has been shown in other studies.25,26 In contrast, regular
exercise has a positive effect on HRV. This has been
described by others for both sympathetic and vagal nerve
activity.27–30
The influence of BMI on HRV is also controversially dis-
cussed in the literature.20,22 We found a small effect of
BMI on SDNN, TP, LF, LF/HF ratio, VLF, and ULF. Self-reported
Figure 1 Percentiles of TP for healthy men and women.
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diabetes and high blood pressure show weak associations in
our study (high blood pressure with TP, LF, VLF, and ULF, dia-
betes with ULF). Both of these cardiovascular risk factors
have also been described as being associated with impaired
autonomic function in the literature.23,31
We found that persons taking ACE-inhibitors had a higher
TP and those taking antiarrhythmics a higher HF, whereas
LF/HF was significantly decreased in the latter group.
Diuretics had a statistically significant negative effect on
TP, LF, VLF, and ULF. Obviously, there is a risk of the con-
founding factors of between medication commonly taken
by the elderly, specifically ACE-inhibitors, antiarrhythmics,
and beta-blockers, and the underlying condition requiring
these chronic medications influencing the results. In these
cases, it can be difficult to separate the effect of a
disease from the effect of the drug used to treat it.
However, in our study, we could show that the effect of
drug intake was opposite to the one of the underlying
disease, suggesting that we looked at the true effect and
not at an effect confounded by diagnosis. Yet, in our
results, the time domain measure SDNN is decreased by
beta-blockers. It is possible that this result captures the
effect of beta-blockers on sympathetic drive, whereas
frequency domain variables, such as TP, may be more sensi-
tive to subtle and fast changes such as enhancement of para-
sympathetic activity by beta-blockers. Effects from
ACE-inhibitors have been demonstrated in smaller clinical
studies: increases in HF32 and LF32,33 and decreases in LF/
HF34,35 have been described. It is interesting to note that
these effects were confirmed in our relatively healthy
cohort. Adrenergic beta-antagonists36–38 and sympathomi-
metics39,40 have been widely studied, whereas little has
been published about the effects of classes I and III anti-
arrhythmic agents,41 calcium channel blockers,42 or diure-
tics on frequency domain HRV.39 We can confirm most of
these effects in our population-based sample, even after
taking all other cardiovascular risk factors into account.
In our study, the laboratory parameters, uric acid and
hs-CRP, were consistently and negatively associated with
all HRV parameters but not the LF/HF ratio. In the litera-
ture, similar effects of hs-CRP have been described in
elderly subjects with no apparent heart disease.43
However, the causal pathway of this association is not
clear. Inflammation may influence autonomic balance or
autonomic imbalance may activate inflammation. No infor-
mation exists in the literature about the association
between uric acid and HRV, but it is known that chronic
renal failure is associated with impaired autonomic function
and reduced HRV.44,45 Of all the laboratory parameters
studied, we found non-HDL cholesterol to have the strongest
effect on both HF and LF. We found no evidence for such an
association in the literature, whereas studies examining the
relation between hypercholesterolaemia and HRV in men
without ischaemic heart disease showed non-uniform
results.46,47
Thus, our findings confirm many of the results of individual
smaller studies on the single or combined effects of drugs,
lifestyle, or risk factors of cardiovascular disease on HRV.
From a clinical point of view, a shortcoming of this study is
the fact that we examined a random sample of the general
population not comparable with cardiac patients. Thus, the
meaning of our results in clinical settings still needs to be
explored.
In this cross-sectional study, we exclusively looked at
people aged 50. In the future, additional age groups
need to be examined and longitudinal assessments need to
be performed, as stated in the report of the Task Force.9
We chose to report SDNN and frequency domain variables.
Although the physiological basis for ULF and VLF power are
far less clear than that for HF and LF power, they have
been shown to be more powerful risk predictors in cardio-
vascular disease.48
To the best of our knowledge, this is the first study simul-
taneously able to assess the contribution of a wide range of
risk factors on HRV and to provide percentile curves for 24 h
HRV for an elderly population. We hope that these data will
help the interpretation of HRV data in the general popu-
lation and the clarification of the role of various factors
influencing HRV.
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Background Exposure to environmental tobacco smoke (ETS) has been shown to increase the risk for cardiovascular
diseases and death, and autonomic dysfunction (specifically, reduced heart rate variability (HRV)) is a
predictor of increased cardiac risk. This study tests the hypothesis that ETS exposure reduces HRV in the
general population and discusses possible pathways.
Methods This cross-sectional study was conducted between 2001 and 2003 and is part of the SAPALDIA (Swiss Cohort
Study on Air Pollution and Lung Diseases in Adults) study.
The analysis included 1218 randomly selected non-smokers aged 50 and above who participated in 24-h
electrocardiogram recordings. Other examinations included an interview, investigating health status
(especially respiratory and cardiovascular health and health relevant behaviours and exposure to ETS) and
measurements of blood pressure, body height and weight.
Results Subjects exposed to ETS at home or at work for more than 2 h/day had a difference of 15% in total power
(95%CI: 26 to 3%), low frequency power (28 to 1%), low/high frequency ratio (26 to 3%) and
18% (29 to 4%) in ultralow frequency power of HRV compared with subjects not exposed to ETS at
home or work. We also found a 2.7% (0.01 to 5.34%) higher heart rate during the recording in exposed
subjects.
Conclusions Exposure to ETS at home and work is associated with lower HRV and with higher heart rate in an ageing
population. Our findings suggest that exposure to ETS increases cardiac risk through disturbances in the
autonomic nervous system.
Keywords Tobacco smoke pollution, heart rate variability, autonomic nervous system, heart rate, blood pressure
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Background
Exposure to environmental tobacco smoke (ETS) and reduced
heart rate variability (HRV) in middle-aged and elderly subjects,1
survivors of myocardial infarction,2 or patients with other
cardiovascular diseases3,4 are both known to be associated with
increased cardiovascular morbidity and mortality.5–10 HRV,
a widely used measure of cardiac autonomic control,11 reflects
autonomic modulation of the rhythmic activity of the sinus
node.11 To date, little has been reported on the association
between ETS exposure and HRV, heart rate, or blood pressure,
the alterations of which may be steps in the pathophysiological
pathway leading from ETS exposure to cardiopulmonary disease.
To our knowledge, the effect of longer-term exposures to ETS on
HRV has not been analysed. Short-term effects have been
described by Pope, who found a reduction in HRV in 16 never
smoking subjects equipped with Holter monitors, who were
moved from the non-smoking section of an airport to the
smoking lounge.12 Reports from the 1991 SAPALDIA (Swiss
Cohort Study on Air Pollution and Lung Diseases in Adults)
study13 describe the effects of ETS on respiratory symptoms in
never smokers14 and on lung function in asthmatics.15 In the
follow-up study (SAPALDIA 2), we also show a higher probability
of the development of asthma in subjects exposed to ETS.16
In SAPALDIA 2, ambulatory 24-h electrocardiograms (ECG) were
performed in a random sample of participants age >50.
This analysis looks at the effect of ETS exposure on HRV
and explores the role of heart rate and blood pressure in this
context.
Materials and methods
Participants
The SAPALDIA cohort study was designed to measure the
health effects of long-term exposure to air pollutants in the
Swiss adult population. Details of its design and objectives
have been reported elsewhere.17,18 In 1991, a random sample of
the Swiss population was recruited from eight areas
featuring distinct geographical and environmental conditions.
SAPALDIA participants were examined in 1991 and 2001–03 for
risk factors of cardiovascular disease, respiratory symptoms,
pulmonary function evolution and development of lung
diseases.
A random sample of 2000 SAPALDIA 2 participants age >50
who agreed to participate were offered a 24-h ECG recording.
Data on smoking status were collected during an extensive
interview led by trained fieldworkers. Among the 1837 persons
having performed the measurements, 1385 reported that
they had not smoked cigarettes, pipes, cigarillos or cigars in
the last 5 years and were included in this study. Self-reports
were confirmed by end-expiratory carbon monoxide (CO)
measurements using EC50 Micro-Smokerlyzers (BEDFONT,
Rochester, UK); 91 participants were excluded because they
had an end-expiratory CO of >7 ppm, indicating that they
might be smokers.19–22 One participant was excluded because
of a myocardial infarction in the previous 3 months and
four because of digitalis intake in the previous 30 days.
None had a cardiac pacer or anaesthesia (narcosis or spinal
anaesthesia) in the 8 days prior to the ambulatory ECG
recording (Figure 1).
ETS exposure was assessed for different environments
by the question ‘How many hours per day are you exposed to
other people’s tobacco smoke (i) at home (ii) at the workplace
(iii) in bars and restaurants (iv) elsewhere?’ We focused on
exposure to ETS at home and work since these two sources
dominate overall exposure in most subjects and because it is
usually easier to recall routine exposure to ETS at home and at
work than in other places. For seven subjects, information on
ETS exposure was missing. On the basis of previous work,14
ETS exposure was categorized into three exposure groups: none,
62h per day but not none, and42h per day.
Cardiovascular risk factors
Blood pressure was measured twice on the left upper arm with
the subject sitting and at rest, by an automatic device (705CP,
OMRON, Tokyo, Japan) according to WHO recommendations.23
Blood pressure values used in the regression model were the
arithmetic mean of the two measurements. High blood pressure
was defined as either a systolic blood pressure
(SBP) >140mmHg, or a diastolic blood pressure (DBP)
>90mmHg, or having answered yes to the question ‘Do you
have the following condition: Hypertension?’
Body height and weight were measured with participants not
wearing any shoes or coats and body mass index (BMI) was
calculated as weight (kg) divided by height squared (m2). For
two participants, information for calculating BMI was missing.
Data on education, hypertension and current medications
were collected during the interview.
The highest degree of education, which is correlated to
income,24 was used as a proxy for social position.
Blood samples were taken from subjects, and several known
cardiovascular risk factors were determined by the Institute for
Clinical Chemistry of the University Hospital Zu¨rich: A Hitachi
Modular Autoanalyser (Rotkreuz, Switzerland); assays from
Roche Diagnostics (Mannheim, Germany) were used to
measure serum levels of uric acid and total cholesterol (both
enzymatic tests) and high-sensitive C-reactive protein (CRP)
was measured with a latex-enhanced immunoturbidimetric
assay. High-density lipoprotein cholesterol (HDL) was measured
with a homogenous assay (Roche diagnostics, Mannheim,
Germany) using Roche Cobas Integra (Rotkreuz, Switzerland).
HDL values were only used if the participants had a
triglyceride level of 69.4mmol/l. As additional atherogenic
markers, the difference between total cholesterol and HDL
(non-HDL-cholesterol) and the ratio between total cholesterol
and HDL were calculated.
Ethical approval for the study was given by the central ethics
committee of the Swiss Academy of Medical Sciences and the
Cantonal Ethics Committees for each of the eight examination
areas; subjects gave informed consent at the examination.
These procedures were in accordance with the recommenda-
tions of the Helsinki Declaration.
HRV data
For 24-h ECG (Holter) recording, digital devices (Aria, Del Mar
Medical Systems, Irvine, CA) with a frequency response
of 0.0540Hz and a resolution of 128 samples/s were
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used. The recorders were hooked up after the interview.
Three leads (V1, altered V3 with the electrode on the left
midclavicular line on the lowest rib and altered V5 with the
electrode on the left midclavicular line on the lowest rib) were
recorded over 24 h. We excluded the first 2 h of recording to
avoid bias from the effects of methacholine administered in the
preceding broncho-challenge test. Recordings with insufficient
quality (n¼ 32) or <18h (n¼ 30) were not used (Figure 1).
Mean duration of the remaining 1218 recordings was
22.3 2.1 h. Participants were asked to follow their regular
daily life and to fill in a time-activity diary during the
recording time.
All recordings were scanned through a StrataScan 563 (Del
Mar) and interpreted with the interactive method, with a final
visual check of the full disclosure. Mean heart rate per minute
was derived from Holter measurements. The length of each
RR interval was manually validated during this step.
Re-sampling was done at 4Hz. Spectral analysis was performed
by the fast Fourier transform method using sliding 256 PTAs
windows for night periods. For 24-h periods, calculations of RR
intervals were made without sliding window, to allow
measurement of ultralow frequency power (ULF) and of very
low frequency power (VLF). Only normal to normal (NN)
intervals were used, with intervals excluded due to ectopy or
artefacts being replaced by holding the previous coupling
interval level throughout the time interval to the next valid
coupling interval. The standard deviation of all normal to
normal RR intervals (SDNN) and the following frequency
domain variables were calculated: total power (60.40Hz), ULF
(60.0033Hz), VLF (0.0033–0.04Hz), low frequency (LF) power
(0.04–0.15Hz), high frequency (HF) power (0.15–0.40Hz) and
the ratio between LF and HF (LF/HF).
Statistical analysis
Because an initial inspection suggested that the distribution of
the residuals was skewed, the HRV values were log-transformed
before further analysis and the results are presented as percent
differences between exposure groups.
We evaluated the effect of ETS on HRV, heart rate and blood
pressure using a multivariable regression model adjusting for
study site, sex, age and age squared, education, BMI, self-
reported diabetes and beta-blocker intake in the previous
30 days (core model). Sensitivity analysis for additional
potential confounders (hypertension, physical activity, alcohol
drinking, cardioactive medication and cardiovascular risk
factors in the blood) and additional analyses for the period
during sleep at night to exclude shorter-term effects were
carried out. To check whether former smoking would have a
residual effect on cardiac autonomic function, we controlled for
smoking status in a further analysis.
To assess differences of proportions and means in the three
ETS exposure groups in Table 1, Chi-squared-tests and the
Kruskal–Wallis test were performed.
Statistical analysis was performed using the software package
Stata 9.2 (Stata corporation, College Station, TX).
Results
Among the 1218 never smokers and former smokers included
in the final study group, 184 (15%) were regularly exposed to
ETS at home or at work: 104 (8.5%) 62h/day, and 80 (6.6%)
42 h/day.
Table 1 gives an overview of the study population0s
characteristics, categorized by ETS exposure. Subjects without
ETS exposure were slightly older, had a lower BMI and drank
less alcohol.
Table 2 shows geometric means of HRV measures, adjusted
for the covariates of the core model, according to ETS exposure.
In subjects exposed42 h/day to ETS at home or at work, total
power (95% CI 26 to 3%), LF (CI 28 to 1%) and LF/HF
(CI 26 to 3%) were 15% lower than in unexposed subjects.
ULF was 18% (CI 29 to 4%) lower. Although results for HF,
VLF and SDNN showed no substantial difference between
exposed and unexposed subjects, the trend was the same as for
the other outcome variables. Similar results emerged when
we stratified for sex (Supplementary data are available at
International Journal of Epidemiology online). In order to test
possible pathways, we analysed heart rate and blood pressure:
the results are shown in Table 3 as arithmetic means adjusted
for the covariates of the core model. Heart rate was 2.7% (CI 0.1
to 5.5%; P¼ 0.049) higher in subjects exposed42 h/day to ETS
than in unexposed subjects. Systolic blood SBP was similar in
the two groups and DBP was 1.9% (3.0 to 2.9%; P¼ 0.174)
higher in subjects exposed to ETS4 2h/day. Unadjusted results
are presented as online supplementary material.
Figure 2 shows the relationship between ETS exposure and
percent difference in LF, heart rate and DBP with control for
all factors of the core model. There were trends for a lower
LF with increasing ETS exposure and for higher heart rate and
DBP with higher ETS exposure at home or work.
Sensitivity analyses
In order to guard against confounding by factors not considered
in the core model, we conducted sensitivity analyses by
including complementary categories of covariates in the model
each at a time: additional control for physical exercise causing
sweating and physical exercise causing slight shortness of
breath did not change the difference in total power between
the reference group and the highest ETS exposure group
Figure 1 Flow chart of participants and exclusion criteria
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(Supplementary data are available at International Journal of
Epidemiology online). Also, no sizeable change of the results was
seen with additional control for hypertension. The difference
in total power between the reference group and the highest
exposure group slightly increased with additional control for
consumption of red wine and alcoholic beverages or for serum
levels of uric acid, high-sensitive CRP and non-HDL cholesterol
or when subjects taking ACE inhibitors, antiarrhythmic
medication, calcium channel blockers, diuretics or sympatho-
mimetics were excluded. Moreover, results were not sensitive to
excluding education from the model. We could also see no
difference in the influence of educational level on HRV between
men and women (data not shown). Additional analyses of HRV
restricted to the sleep period according to diary information
showed results similar to the analyses of the 24-h measures.
On average, LF power at night was 15.1% (CI: 25 to 4%;
P¼ 0.009) lower in subjects exposed to ETS >2 h/day than in
the reference group. Additional controlling for smoking status
showed little evidence for a residual effect of former smoking.
The strongest effect of former smoking was seen for ULF with
a 5% lower ULF (CI 13 to 2%) in former smokers than in
never smokers.
Discussion
In recent years, there has been increasing evidence that ETS
exposure affects cardiovascular health.5–10,25–27 Our study pro-
vides further evidence that ETS exposure is associated with
cardiac autonomic dysregulation, which may be an intermediate
step in the pathway to cardiac instability.4,28 Our observations
are in agreement with the findings of Pope, who described a
short-term decrease in all HRV domains after acute exposure to
ETS, but with relatively high standard errors in HF.12
LF, which is considered to represent both sympathetic and
parasympathetic activities,29 was lower in subjects with higher
ETS exposure. We also observed ETS-associated increases in
heart rate and, more weakly, in DBP, consistent with increases
in sympathetic stimulation.
Since few people are exposed to ETS during sleep, we
restricted analyses to the sleep period, when acute exposure
can be excluded and found results similar to those of the
24-h measures. Therefore, we think that our findings do not
reflect acute responses.
Table 1 Overview of the study population baseline characteristics by
exposure group
ETS exposure None 62h/day 42h/day
n 1034 (84.9%) 104 (8.5%) 80 (6.6%)
aFemale 556 (53.8%) 53 (51.0%) 41 (51.3%)
aAge (years) 61.0 (SD 6.4) 59.8 (SD 6.2) 58.4 (SD 5.0)
Blood pressure
systolic (mmHg) 132.7 (SD 19.7) 133.7 (SD 21.0) 131.5 (SD 18.6)
diastolic (mmHg) 81.7 (SD 10.8) 82.4 (SD 10.4) 83.5 (SD 11.3)
aBMI (kg/m2) 26.5 (SD 4.3) 27.8 (SD 4.8) 27.4 (SD 4.3)
aSelf-reported
diabetes
44 (4.3%) 4 (3.9%) 3 (3.8%)
aEducation
Primary 93 (9.0%) 15 (14.4%) 4 (5.0%)
Secondary 660 (63.8%) 69 (66.4%) 59 (73.8%)
Tertiary 281 (27.2%) 20 (19.2%) 17 (21.3%)
Light physical activity
62 d/w 496 (48.1%) 55 (52.9%) 42 (52.5%)
42 d/w 536 (51.9%) 49 (47.1%) 38 (47.5%)
Heavy physical activity
61 h/w 763 (74.2%) 77 (74.8%) 54 (67.5%)
41 h/w 266 (25.9%) 26 (25.2%) 26 (32.5%)
Alcohol
<1 glass/day 776 (75.1%) 66 (63.5%) 56 (70%)
>1 glass/day 258 (25.0%) 38 (36.5%) 24 (30.0%)
aBeta-blocker
medication
123 (11.9%) 17 (16.4%) 8 (10.0%)
ACE-inhibitor 64 (6.2%) 6 (5.8%) 6 (7.5%)
Antiarrhythmic
drugs class Iþ III
4 (0.4%) 0 (0.0%) 1 (1.3%)
Calcium
channel blocker
45 (4.4%) 7 (6.7%) 5 (6.3%)
Diuretics 43 (4.2%) 6 (5.8%) 2 (2.5%)
Sympathomimetics 36 (3.5%) 5 (4.8%) 0 (0.0%)
Uric acid [mol/l] 321.1 (SD 81.4) 332.6 (SD 79.0) 331.7 (SD 93.4)
Hs-CRP [mg/l] 2.6 (SD 5.9) 2.4 (SD 4.8) 2.2 (SD 3.2)
Non-HDL-cholesterol
[mmol/l]
4.7 (SD 1.1) 4.8 (SD 1.2) 4.9 (SD 1.2)
a Covariates of the core model.
Table 2 Adjusteda geometric mean HRV according to ETS exposure
HRV variable No current ETS exp. ETS 62h/day ETS42h/day
n 1034 104 80
SDNN [ms] 134.0 (131.8, 136.1) 134.0 (127.4, 140.9) 129.3 (122.1, 136.9)
Total Power [ms2] 3866.7 (3729.6, 4008.8) 3712.1 (3308.78,4164.5) 3270.1 (2868.7, 3727.7)
HF [ms2] 71.3 (67.5, 75.2) 61.5 (51.8, 73.1) 71.2 (58.5, 86.6)
LF [ms2] 233.6 (224.0, 243.7) 210.3(183.8, 240.6) 197.7 (169.6, 230.5)
LF/HF 3.3 (3.2, 3.4) 3.4 (3.0, 3.8) 2.8 (2.4, 3.2)
VLF [ms2] 626.1 (603.4, 649.7) 598.9 (532.5, 673.7) 560.0 (489.8, 640.3)
ULF [ms2] 2741.3 (2634.1, 2852.8) 2671.6 (2352.9, 3033.6) 2256.3 (1952.4, 2607.6)
Values in parentheses are 95% CIs.
a Adjusted for study site, gender, age, education, BMI, diabetes and beta-blocker intake.
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ETS may affect autonomic control of the heart through
activation of neural receptors of the respiratory tract. On the
other hand, gaseous components, soluble fractions of the
particulate component and ultrafine particle components of
ETS may be absorbed in the lung and have additional systemic
effects. In the experimental setting, chronic ETS exposure has
been shown to increase proinflammatory cytokines and arterial
resistance, to decrease concentrations of antioxidants and
to increase lipid peroxidation.30 We found no evidence of
ETS-associated increases in inflammation as measured by CRP
and other causal mechanisms may predominate with low-grade
chronic exposure. Recent work by Bartoli and colleagues31
suggests that particle exposures alter barometric reflexes, a
pathway through which ETS exposure might also influence
HRV.31 Ultrafine particles are associated with oxidative stress,32
as well as with reduced HRV.33
To better understand why exposure to ETS is associated
with lower HRV, it is interesting to compare these effects
with those of active smoking on HRV. In a recent publication,
we showed that active smokers had lower overall and low
to ULF HRV measures than never smokers, which reflect the
dynamic features of sympathetic cardiovascular modulation,
analogous to the results described in this work. The effect of
current smoking compared with never smoking was also
of magnitude similar to the effect shown in this study.17
Thus, we could deduce that active smoking and passive
smoking harm the cardiovascular system through similar toxic
substances.
The consequence of autonomic dysfunction caused by
pollutants such as ETS, air pollution and other factors can be
an increased risk for ventricular arrhythmia in vulnerable
patients or a contribution to the instability of a vascular plaque,
eventually leading to cardiac death.34–36
We measured exposure to ETS using questionnaire data and
used CO measures to validate smoking status. We believe that
self-reporting gives a better estimate for exposure to ETS during
the past year than measurement of biomarkers, which reflect
the level of exposure to passive smoking in the immediate past
with half-lifes of only several hours.37 In the literature,
measurement of exhaled CO in combination with self-reporting
has been described to provide an acceptable degree of discrimi-
nation between smokers and non-smokers.37
Reporting bias might have occurred if participants with lower
HRV had been more likely to report passive exposure to
cigarette smoke. However, this is very unlikely since HRV is not
readily apparent to the participant. Moreover, exposure to ETS
is generally associated with respiratory symptoms and to a
much lesser degree with cardiovascular health. In addition,
we observed a 13% increase of individuals not exposed to
ETS compared with 1991—which would point towards
under—rather than overreporting of ETS.
A recent study has shown that social position expressed as low
employment grade is associated with low HRV.38 In our study,
the effect of ETS exposure on the HRV parameters did not change
Figure 2 Hours of environmental tobacco smoke exposure at home
and at work and low frequency heart rate variability, heart rate and
diastolic blood pressure and respective 95% confidence intervals,
adjusted for study site, sex, age, education, BMI, diabetes and
beta-blocker intake
Table 3 Adjusteda geometric means of heart rate and blood pressure according to ETS exposure
Variable No current ETS exp. ETS 62h/day ETS42h/day
Heart rate [bpm] 73.4 (72.9, 73.9) 73.4 (71.8, 75.1) 75.3 (73.5, 77.2)
SBP [mmHg] 132.7 (131.6, 133.8) 133.5 (130.1, 136.9) 132.6 (128.7, 136.5)
DBP [mmHg] 81.7 (81.1, 82.3) 82.1 (80.2, 84.0) 83.3 (81.1, 85.5)
Values in parentheses are 95% CIs.
SBP: systolic blood pressure, DBP: diastolic blood pressure.
a Adjusted for study site, gender, age, education, BMI, diabetes and beta-blocker intake.
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when we did not account for level of education, indicating that
these results are not likely to be confounded by social position.
In conclusion, our results contribute to the evidence that
exposure to second-hand smoke increases cardiac risk through
cardiac autonomic dysfunction. Health benefits can be expected
if people are protected from passive smoking.
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(HRV), a clinically relevant predictor of 
cardiovascular morbidity and mortality, 
and whether adverse effects of obesity and 
weight gain on HRV were modified by 
regular exercise. 
24-hour electrocardiograms were recorded 
in 1712 randomly selected SAPALDIA 
participants aged ≥50, for whom BMI was 
assessed in the years 1991 and 2001-2003. 
Other examinations included an interview 
investigating health status (especially 
respiratory and cardiovascular health and 
health relevant behaviours including 
physical activity) and measurements of 
blood pressure, body height and weight. 
The association between regular physical 
activity and HRV and interactions with 
BMI and BMI change was assessed in 
multivariable linear regression analyses. 
Compared to sedentary obese subjects, 
SDNN (standard deviation of all RR 
intervals) was 14% (95% CI: 8-20%) 
higher in sedentary normal weight 
subjects; 19% (CI: 12-27%) higher in 
normal weight subjects exercising 
regularly ≥ 2h/week; and 19% (CI:11 -
28%) higher in obese subjects exercising 
regularly ≥ 2h/week. 
Compared with sedentary subjects who 
gained weight, those who gained weight 
but did exercise regularly had a 13% 
higher SDNN (CI: 7-20%). 
Regular physical exercise has strong 
beneficial effects on cardiac autonomic 
nervous function and thus appears to offset 
the negative effect of obesity on HRV. 
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Introduction 
 
Obesity and weight gain are imposing a 
growing threat to world health, as in many 
countries 20-30% of adults are categorized 
as clinically obese, and their number is still 
increasing (World Health Organization 
1999; World Health Organization 2002). 
Many studies have demonstrated an 
association of both a high body mass index 
(BMI) and a sedentary lifestyle with 
greater risk for cardiovascular disease 
(Fang et al. 2003; Wei et al. 1999). 
In the SAPALDIA (Swiss cohort study 
on Air Pollution and Lung Diseases in 
Adults) study of a large sample of Swiss 
adults, we confirmed the relation of 
reduced heart rate variability (HRV) with 
increased BMI (Felber Dietrich et al. 
2006). Heart rate variability refers to the 
beat-to-beat variation in heart rate and is a 
marker of cardiac autonomic control 
(Kleiger et al. 2005). Reduced HRV 
predicts increased risk of cardiovascular 
disease and mortality in longitudinal 
studies (Bigger et al. 1993; Kleiger et al. 
1987). Other studies have noted that 
increased BMI is associated with reduced 
HRV, which has been attributed to 
decreased adreno-receptor responsiveness, 
withdrawal of parasympathetic tone and/or 
increased sympathetic activity (Fraley et 
al. 2005; Ramaekers et al. 1998). Likewise, 
weight changes have been associated with 
changes in HRV (Hirsch et al. 1991; 
Poirier et al. 2003). There is also evidence 
from the literature, that regular moderate 
endurance training as opposed to strength 
training has a positive effect on HRV 
(Hottenrott et al. 2006). Based on these 
findings, we wanted to test the hypothesis 
within the prospective SAPALDIA cohort, 
that regular exercise is associated with 
improved HRV, and that adverse effects of 
obesity and weight gain on HRV can be 
modified by regular exercise. 
 
 
Methods 
 
This study is part of the SAPALDIA 
cohort study, which was primarily 
designed to assess health effects from 
long-term exposure to air pollutants in the 
Swiss adult population. Details of its 
design and objectives have been reported 
elsewhere (Ackermann-Liebrich et al. 
2005; Martin et al. 1997). In brief, a 
random sample of the Swiss population 
was recruited in 1991 from eight areas 
featuring distinct geographical and 
environmental conditions. 9651 
participants received intensive health 
examinations and a detailed health 
interview in 1991. In 2001-2003, we were 
able to re-examine 8047 of the original 
participants and to assess HRV in a 
random selection (n=1846: 955 women, 
891 men) of the 4417 participants aged 
≥50 years by 24-hour ECGs. Exclusion 
criteria were general or spinal anaesthesia 
within eight days prior to the ambulatory 
ECG recording (n=5), having had a 
myocardial infarction within 3 months 
prior to the examination (n=2), and taking 
digitalis (n=6); nobody had an artificial 
pacemaker. Exclusion of  recordings 
showing atrial fibrillation (n=12), 
recordings of <18h (recommendations of 
the Task Force of the European Society of 
Cardiology and the North American 
Society of Pacing and Electrophysiology 
(North American Society of Pacing and 
Electrophysiology 1996)) (n=73), and 
recordings of insufficient quality (n=6) left 
1742 datasets. We had complete 
information on 1718 subjects for analysis 
of HRV involving BMI and exercise and 
on 1712 subjects for analysis involving 
weight gain from baseline to follow-up. 
For statistical reasons, 15 subjects being 
underweight at follow-up were excluded 
from analyses where BMI was used as a 
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categorical variable, leaving 1703 records 
for analyses. 
 
HRV measurements and analyses 
For the Holter recording, digital devices 
(Aria, Del Mar Medical Systems, Irvine, 
CA, USA) with a frequency response of 
0.05–40Hz and a resolution of 128 
samples/s were used. Three leads (V1, 
altered V3 with the electrode on the left 
midclavicular line on the lowest rib, and 
altered V5 with the electrode on the left 
anterior axillary line on the lowest rib) 
were recorded over 24 hours. The mean 
duration of the Holter recordings was 22.3 
(SD 2.1) hours. 
All recordings were scanned through a 
StrataScan 563 (Del Mar) and interpreted 
using the interactive method, with a final 
visual check on the full disclosure. The 
length of each RR interval was manually 
validated during this step. Resampling was 
made at 4Hz. Spectral analysis was 
performed by the fast Fourier transform 
method. Only normal-to-normal intervals 
were used, with intervals excluded due to 
ectopy or artefacts being replaced by 
holding the previous coupling interval 
level throughout the time interval to the 
next valid coupling interval. The standard 
deviation of all normal RR (NN) intervals 
(SDNN), which is a summary measure of 
HRV and the following frequency domain 
variables have been calculated: Total 
power (TP) (≤0.40 Hz),  LF power (0.04–
0.15Hz), high frequency (HF) power 
(0.15–0.40Hz) and the LF/HF ratio. HF 
power is an index of the parasympathetic 
modulation of heart rate, whereas LF 
power is an index of the combined 
parasympathetic and sympathetic 
modulation of heart rate. LF/HF represents 
the sympatho-vagal balance (North 
American Society of Pacing and 
Electrophysiology 1996; Sztajzel 2004). 
In order to avoid a biased result due to 
methacholine challenge, which was part of 
the SAPALDIA lung function testing and 
which, for practical reasons, was 
performed before the Holter recording, we 
excluded the first two hours of all 
recordings (van der Woude et al. 2004).  
Holter recordings were made between 
August 2001 and March 2003. Recorders 
were placed on participants having given 
consent after a detailed health interview. 
Participants were asked to follow their 
regular daily routine and to complete a 
time-activity diary during the recording 
period.  
 
Other measurements 
 
Body height and weight were measured 
with participants not wearing any shoes or 
coats and body mass index was calculated 
as weight (kg) divided by height squared 
(m2). Four BMI groups were distinguished 
according to the WHO definitions (World 
Health Organization 1999): underweight (< 
18.5 kg/m2), normal weight (18.5-24.9 
kg/m2), overweight (25.0-29.9 kg/m2) and 
obese (≥ 30kg/m 2). In the 1991 cross-
sectional study, body weight was asked. 
Weight gain was defined as being in a 
higher BMI category in the follow-up 
study compared to the first survey. 
The amount of physical activity 
(Question: 'How many hours a week do 
you usually exercise such that you get out 
of breath or sweat?') (The European 
Community Respiratory Health Survey II 
2000) and data on smoking, education, 
diabetes, level of daytime sleepiness 
(Epworth sleepiness scale) (Johns 1991; 
Johns 1993) and current medications status 
were assessed during a standardized 
interview which was led by trained 
fieldworkers. The participants were 
divided into tertiles of exercise: no regular 
physical exercise, ½ to 1 hour and ≥ 2 
hours of regular physical exercise. 
Blood pressure was measured twice at 
rest in the sitting position on the left upper 
arm by an automatic device (705CP, 
OMRON, Tokyo, Japan) according to 
WHO recommendations(World Health 
Organization 1996). Blood pressure values 
used in the regression model were obtained 
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by averaging the two measurements. 
Having high blood pressure was defined as 
either having a systolic blood pressure > 
140 mmHg, or a diastolic blood pressure > 
90 mmHg, or having answered yes to the 
question "Do you have the following 
condition: Hypertension?". 
The highest degree of education was 
used as a proxy for social position. 
Blood samples were taken from the 
subjects and known cardiovascular risk 
factors have been determined by the 
Institute for Clinical Chemistry of the 
University Hospital Zürich: A Hitachi 
Modular Autoanalyser (Rotkreuz, 
Switzerland) and assays from Roche 
Diagnostics (Mannheim, Germany) have 
been used to measure serum levels of uric 
acid, triglycerides and total cholesterol (all 
enzymatic tests). High sensitive C-reactive 
protein (CRP) was measured using a latex-
enhanced immunoturbidimetric assay. 
High-density lipoprotein cholesterol 
(HDL) was measured with a homogenous 
assay (Roche diagnostics, Mannheim, 
Germany) using Roche Cobas Integra 
(Rotkreuz, Switzerland). HDL values were 
only used if the participants had a 
triglyceride level of 9.4 mmol/l or lower. 
As additional atherogenic markers, the 
difference between total cholesterol and 
HDL (non-HDL-cholesterol) and the ratio 
between total cholesterol and HDL were 
calculated. 
Ethical approval for the study was 
given by the central Ethics Committee of 
the Swiss Academy of Medical Sciences 
and the Cantonal Ethics Committees for 
each of the eight examination areas and 
subjects signed an informed consent at the 
examination. 
 
Statistical methods 
 
Because an initial inspection suggested that 
the distribution of the residuals was 
skewed, the HRV-values were log-
transformed for further analysis and the 
results are presented as percent difference 
between the exposure groups as well as 
geometric means. 
To calculate the effect of BMI and 
physical activity on HRV, we used a 
multivariable regression model including 
variables known from a previous study to 
influence HRV(study site, sex, age and age 
squared, education, self-reported diabetes, 
hypertension, smoking status and beta-
blocker intake in the previous 30 days) 
(Felber Dietrich et al. 2006). 
 
 
Table 1 Baseline characteristics of the study population (n= 1703) 
BMI normal weight overweight obese 
n 636 (37%) 723 (43%) 344 (20%) 
Female sex 400 (63%) 291 (40%) 180 (52%) 
Current smokers 135 (21%) 139 (19%) 58 (17%) 
Tertiary education 178 (28%) 189 (26%) 67 (20%) 
Diabetes 10 (2%) 27 (4%) 34 (10%) 
Beta-blocker intake 40 (6%) 88 (12%) 58 (17%) 
Higher BMI cat. in follow-up 17 (3%) 348 (48%) 223 (65%) 
no regular exercise 264 (42%) 295 (41%) 152 (44%) 
½ - 1 h/week exercise 204 (32%) 243 (34%) 113 (33%) 
≥2 h/week exercise 168 (26%) 185 (26%) 79 (23%) 
Symptoms of chronic bronchitis 97 (15%) 115 (16%) 60 (17%) 
Diuretic intake 8 (1%) 25 (4%) 27 (8%) 
Sympathomimetic intake 11 (2%) 29 (4%) 13 (4%) 
Calcium channel blocker 13 (2%) 37 (5%) 31 (9%) 
ACE inhibitor intake 23 (4%) 49 (7%) 36 (11%) 
Mean heart rate (bpm) 74 (SD 9.7) 74 (SD 9.0) 75 (SD 9.1) 
Systolic blood pressure (mmHg) 125 (SD 19.0) 136 (SD 18.6) 138 (SD 17.0) 
Diastolic blood pressure (mmHg) 78 (SD 10.2) 84 (SD 10.1) 85 (SD 10.0) 
Age (years) 59.4 (SD 6.3) 60.8 (SD 6.2) 61.3 (SD 6.1) 
Non-HDL cholesterol (mmol/L) 4.6 (SD 1.1) 4.9 (SD 1.2) 4.8 (SD 1.0) 
Uric acid (μmol/L) 288.1 (SD 75.1) 341.8 (SD 79.9) 359.8 (SD 84.1) 
C-reactive protein (mg/L) 1.9 (SD 4.5) 2.5 (SD 5.5) 3.9 (SD 5.5) 
Epworth sleep score 6.3 (SD 3.6) 6.4 (SD 3.5) 7.0 (SD 3.8) 
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Table 2 Adjusteda geometric mean (GM) of HRV in different exercise categories 
BMI Normal weight Overweight Obese 
 Exercise (h/week) GM 95% CI GM 95% CI GM 95% CI 
SDNN (ms) None 131.8 (127.5, 136.3) 128.8 (124.9, 132.8) 115.9 (111.0, 121.1) 
½ - 1  135.1 (130.2, 140.2) 131.3 (127.0, 135.8) 127.0 (120.9, 133.5) 
≥ 2 138.3 (132.8, 144.0) 137.3 (132.1, 142.8) 137.8 (129.9, 146.2) 
Total power (ms2) None 3733.2 (3458.6, 4029.6) 3459.4 (3223.6, 3712.6) 3018.3 (2732.1, 3334.5) 
½ - 1 3816.4 (3504.8, 4155.7) 3689.6 (3415.7, 3985.4) 3517.4 (3141.0, 3938.8) 
≥ 2 4081.3 (3717.0, 4481.4) 3725.3 (3407.3, 4072.9) 3904.0 (3410.0, 4469.7) 
HF (ms2) None 65.1 (58.0, 73.1) 68.6 (61.6, 76.3) 62.0 (53.3, 72.0) 
½ - 1 67.1 (59.0, 76.3) 64.4 (57.4, 72.4) 71.0 (59.8, 84.2) 
≥ 2 69.1 (60.0, 80.0) 77.1 (67.4, 88.2) 79.8 (65.1, 97.9) 
LF (ms2) None 206.6 (188.9, 225.9) 217.7 (200.4, 236.4) 167.4 (148.9, 188.1) 
½ - 1 235.2 (212.9, 259.9) 223.2 (203.9, 244.3) 207.4 (181.6, 236.8) 
≥ 2 247.4 (221.7, 276.0) 240.0 (216.2, 266.5) 211.9 (180.9, 248.4) 
LF/HF None 3.2 (2.9, 3.4) 3.2 (3.0, 3.4) 2.8 (2.5, 3.1) 
½ - 1 3.5 (3.2, 3.8) 3.5 (3.2, 3.8) 2.9 (2.6, 3.3) 
≥ 2 3.6 (3.3, 3.9) 3.1 (2.8, 3.4) 2.7 (2.3, 3.0) 
a adjusted for sex, age, age squared, study site, education, diabetes, hypertension, beta-blocker intake and smoking status 
 
 
We investigated modification of the 
effect of BMI by physical activity by 
introducing according interactions terms 
between exercise and BMI categories into 
the multivariable regression model. 
Sensitivity analyses screening for 
additional potential confounders (Epworth 
sleepiness score >10 vs ≤6; diuretics, 
sympathomimetics, calcium-channel 
blockers and angiotensin converting 
enzyme inhibitor intake during the 
previous 30 days; non-HDL-cholesterol, 
uric acid and high sensitive CRP levels) 
were carried out. 
Statistical analyses were performed 
using Stata 9.2 (Stata corporation, College 
Station, Texas). 
 
 
Results 
 
Mean age of the population was 60 years 
(50-73 years). Baseline characteristics of 
the 1703 study participants by exercise 
category are given in Table 1. 37% of the 
study population were normal weight, 43% 
were overweight, and 20% obese, with a 
homogeneous distribution across exercise 
categories. Less than 1% of the study 
participants were morbidly obese. Between 
the first and the second survey, 35% had 
gained weight so that they changed into a 
higher BMI category. There was a higher 
proportion of women and current smokers 
in the normal weight group, but fewer 
subjects with diabetes or subjects taking 
beta-blockers, diuretics or angiotensin 
converting enzyme (ACE) inhibitor. In that 
same group, subjects had lower average 
heart rate and systolic and diastolic blood 
pressure, and they were on average better 
educated and slightly younger; they also 
had lower levels of non-HDL-cholesterol, 
uric acid or C-reactive protein. 
Table 2 exhibits the adjusted means of 
HRV parameters for different BMI and 
exercise categories. Within each BMI 
category, subjects regularly exercising ≥ 2 
hours per week had higher HRV than 
sedentary subjects. Even obese 
subjectsexercising ≥ 2 hours had a higher 
HRV than sedentary normal weight 
subjects. 
Using a cubic model for BMI 
(continuous), subjects who exercise 
regularly had higher SDNN than their 
sedentary peers (figure showing curves of 
adjusted geometric means for the three 
exercise categories shown in annex 8). As 
can be deducted from these curves, SDNN 
in physically active subjects (≥ 2 hours of 
exercise per week) did not depend on BMI. 
Figure 1 compares SDNN for obese 
subjects not exercising (reference group) to 
other BMI and exercise categories. 
Compared to obese subjects not exercising 
regularly, overweight subjects not 
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Fig. 1 Compares SDNN for obese subjects not exercising 
(reference group) to other subject groups stratified by BMI 
category (normal, overweight, obese) and exercise status. 
Normal weight is defined as 18.5 ≤ BMI < 25.0 kg/m 2; 
overweight 25.0 ≤ BMI < 30.0 kg/m 2; obese 30.0 ≤ BMI 
kg/m2). Effect estimates and 95% confidence intervals. a 
Difference to sedentary obese subjects. b Difference to 
sedentary overweight subjects (95% CI: -0.196, -0.022). c 
Difference to sedentary normal weight subjects (95% CI: -
0.214, -0,036) 
 
exercising had an 11% [95% confidence 
interval (95% CI: 5 to 17%)] higher SDNN 
and normal weight subjects not exercising 
had a 14% (95% CI: 8 to 20%) higher 
SDNN. 
Regardless of weight, the improvement 
in SDNN was greatest for those who 
exercised regularly ≥ 2 hours per week. 
Compared to obese subjects not exercising, 
among those who exercised regularly, 
SDNN was 19% (95% CI: 12 to 27%) 
higher in normal weight subjects, 18% 
(95% CI: 12 to 26%) higher in overweight 
subjects, and 19% (95% CI: 11 to 28%) 
higher in obese subjects. The difference in 
SDNN within each BMI category between 
subjects exercising regularly ≥ 2 hours and 
sedentary subjects was highest in obese 
subjects. Regular exercise modified the 
relation of obesity with SDNN (95% CI: -
0.214 to -0.036 for the difference in the 
effect of obesity compared to normal 
weight between subjects exercising 
regularly (i.e., ≥ 2 hours) and subjects with 
a sedentary lifestyle) (supplementary Table 
1 shown in annex 9). 
Fig. 2 Average percent increase and 95% confidence interval 
in measures of HRV (SDNN, total power, HF, LF) in obese 
subjects exercising ≥ 2 h/week, compared to sedentary obese 
subjects. 
 
 
Compared to sedentary obese subjects, 
obese subjects exercising regularly also 
had 29% (95% CI: 9 to 53%) higher total 
power, 29% (95% CI: 0 to 66%) higher 
HF, 27% (95% CI: 4 to 54%) higher LF 
(Figure 2) and a 2% (95% CI: -17 to 16%) 
lower LF/HF. 
Next, we analysed the influence of 
weight gain between the first survey and 
the follow-up survey on HRV. Weight gain 
is defined as changing into a higher BMI 
category—e.g., becoming overweight or 
obese. Compared with subjects who gained 
weight and did not exercise regularly, 
those who gained weight but did exercise 
regularly had a 13% higher SDNN (95% 
CI: 7 to 20%), 16% higher total power 
(95% CI: 2 to 32%), 25% higher HF (95% 
CI: 3 to 52%), 24% higher LF (95% CI: 6 
to 44%) and a 1% (95% CI: -14 to 12%) 
lower LF/HF (Figure 3). 
These associations were not due to 
a reduction in heart rate with exercise as 
there was no evidence for a change when 
heart rate was introduced into the models 
(Table 3). Mean 24-hour heart rate in 
physically active was 74 bpm (95% CI: 72 
to 76 bpm) as opposed to 76 bpm (95% CI: 
74 to 77 bpm) in inactive obese. 
 
Sensitivity analyses 
 
We tested the robustness of the results by 
including additional potential confounders 
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Fig. 3 Average percent increase in measures of HRV 
(SDNN, total power, HF, LF) in subjects with weight gain 
exercising ≥ 2 h/week, compared to sedentary subjects with 
weight gain. Weight gain is defined as changing to a higher 
weight category (e.g., becoming overweight or obese) 
 
into the model. Table 3 shows that daytime 
sleepiness, symptoms of chronic 
bronchitis, heart rate, cardioactive 
medication intake or cardiovascular risk 
markers in the blood did not sizeably 
change the effect estimates. 
We also evaluated whether daytime 
activity was responsible for HRV 
differences between populations with 
higher levels of exercise compared to 
populations with low levels of exercise. 
Although the estimates for the sleeping 
periods at night were different to the ones 
for the 24-hour periods, the relation 
between the different groups was similar to 
the one of the 24-hour periods, which 
include active periods (supplementary 
Table 2 shown in annex 9). 
 
 
Discussion 
 
This study shows that middle-aged and 
elderly obese subjects who were regularly 
physically active had a higher HRV than 
their sedentary peers even after taking into 
account the effects of sex, age, study site, 
education, diabetes, hypertension, beta-
blocker intake and smoking status. In 
addition, the improvement in HRV 
associated with exercise was similar for 
obese and normal weight subjects. Thus, 
our data suggest that exercise improves 
autonomic function as measured by HRV. 
Analogously to the recently published 
results of Sui et al. of their study on 
cardiorespiratory fitness and adiposity as 
mortality predictors in older adults (Sui et 
al. 2007), we found that lower autonomic 
activity among inactive subjects was 
related to body mass index: inactive 
subjects who were normal weight had 
lower HRV than normal weight exercising 
subjects, but higher than inactive obese 
subjects. 
Several potential sources of bias were 
considered in this study. Smoking, diabetes 
or hypertension, all known to have an 
impact on HRV (Felber Dietrich et al. 
2006), were controlled for in the baseline 
analysis. Obesity is also associated with 
obstructive sleep apnoea syndrome 
(OSAS) (Resta et al. 2001), which in turn, 
has a strong influence on the autonomic 
nervous system (Narkiewicz and Somers 
2003). Even more, obese patients with 
OSAS who loose weight experience an 
improvement in the severity of OSAS, as 
well as in blood pressure and cardiac 
autonomic regulation (Kansanen et al. 
1998). We addressed this issue by 
additionally controlling for daytime 
sleepiness in sensitivity analyses but found 
no indication of such confounding. 
Furthermore, we were able to demonstrate 
that the observed differences in HRV 
between groups were not caused by 
differences in health status represented by 
symptoms of chronic bronchitis, intake of 
 
 
Table 3 Sensitivity analyses adding different variables to the 
baseline model with the natural logarithm of SDNN as 
outcome variable 
 Effect 
estimatea 
95% CI 
Baseline analysis 19% 11-28% 
+ Daytime sleepinessb 23% 12-35% 
+ Symptoms of chronic bronchitisc 19% 10-28% 
+ Heart rate 16%   9-24% 
+Medicationd 19% 10-28% 
+ Cardiovascular risk markers in the 
bloode 
20% 11-29% 
a Estimated %-increase in SDNN associated with regular 
physical (as compared to a sedentary way of life) exercise in 
obese, adjusted for sex, age, age squared, study site, 
education, diabetes, hypertension, beta-blocker intake and 
smoking status 
b Epworth sleepiness score >10 vs. ≤6 
c questionnaire data: "regular cough or phlegm, during the 
day or at night" 
d diuretics, sympathomimetics, calcium channel blockers, 
angiotensin converting enzyme inhibitors 
e non-HDL-cholesterol, uric acid, high sensitive c-reactive 
protein  
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cardioactive medication or cardiovascular 
risk markers in the blood. We also 
excluded the first two hours of all 
recordings in order to avoid a biased result 
due to methacholine challenge, after which 
full recovery without application of a beta-
agonist takes 33.6 minutes (1-75 minutes) 
(van der Woude et al. 2004). Being a 
muscarinic receptor agonist, methacholine 
would lead to an increase in high 
frequency power. 
Our findings are consistent with results 
from intervention trials comparing the 
beneficial effects of exercise and weight 
loss. Oberbach and colleagues have found 
that increases in adiponectin levels after 
four weeks of physical training 
disproportionally exceeded the beneficial 
effects of reduced percent body fat and 
increased fitness level (Oberbach et al. 
2006). In other studies, three-month 
aerobic exercise intervention in overweight 
and obese subjects increased tissue-type 
plasminogen activator without evidence of 
changes in body mass or adiposity (Van 
Guilder et al. 2005), and 12 weeks of 
aerobic training improved insulin 
sensitivity in overweight and obese girls 
without change in body weight, percent 
body fat and concentrations of 
inflammatory markers (Nassis et al. 2005). 
There are several limitations of this 
study. One part of the study was cross-
sectional in design - and hence causality 
cannot be inferred from existing 
associations. However, we were able to 
assess weight gain prospectively in the 
whole population and the fact that weight 
gain is showing the same effect strengthens 
the argument for a causal relationship. 
Our physical activity data give an 
overview of the subjects' activity during a 
relatively recent period; they do not cover 
lifetime or adulthood exercise. Moreover, 
they may include anaerobic exercise. The 
data on physical activity were self-
reported, as in most epidemiological 
studies (US Department of Health and 
Human Services 1996). Over-reporting of 
physical activity, the only conceivable 
form of reporting bias in this context, 
would have led to an underestimation of 
the effect size. Nonetheless, the physical 
activity questionnaire that we used has 
been previously validated (Washburn et al. 
1990) and used in other epidemiological 
studies. The comparative study concluded 
that self-reported sweat hours are suitable 
for distinguishing active from inactive 
subjects in epidemiological surveys. Our 
three activity categories allowed for such a 
distinction. In the European Community 
Respiratory Health Survey physical 
activity level assessed by the same tool 
was predictive of bronchial 
hyperresponsiveness (Shaaban et al. 2007). 
Other studies have used other exercise 
categories; e.g. the Nurses Health Study 
used four categories from zero, moderate, 
to vigorous exercise, to ≥4 hours/week of 
vigorous exercise, showing that women 
who exercised ≥4 hours/week had a 
reduced risk for sudden cardiac death 
compared to those not being physically 
active (Whang et al. 2006). The Women's 
Health Study showed that even as little as 
1 to 1.5 hours of light-to-moderate activity 
are associated with lower coronary heart 
disease rates (Lee et al. 2001), which puts 
more emphasis on our results. 
A given BMI may not correspond to 
the same degree of fatness in different 
people. In addition, the percentage of body 
fat mass is higher in women than in men 
for equivalent BMI (Ross et al. 1994). 
However, different studies have shown that 
BMI does sufficiently coincide with the 
degree of body fatness when adjusting for 
age and sex (Gallagher et al. 1996; 
Movsesyan et al. 2003). Moreover, the 
discriminatory power for body fat and lean 
mass increases with the value of BMI and 
is high in obese people for which our 
results are most pronounced (Romero-
Corral et al. 2006). 
A major strength of the present study 
was the large number of participants. 
Additionally, detailed information was 
available for numerous cardiovascular risk 
factors, allowing for control of potential 
confounders. 
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In conclusion, our results suggest that 
regular physical exercise has strong 
beneficial effects on cardiac autonomic 
nervous function, a clinically relevant 
predictor of cardiovascular morbidity and 
mortality and that exercise may offset the 
negative effect of obesity. 
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5. Summary of main findings 
 
5.1 Determining factors and reference values 
Prevalence of cardiovascular risk factors in male and female participants of the study 
In this study, we could determine the prevalence of cardiovascular risk factors in male and 
female participants of the SAPALDIA cohort study and their influence on measurements of 
HRV. Men were more frequently current smokers (23% vs. 16%), drank on average more 
alcoholic beverages (41% vs. 18% ≥ 1 glass of alcohol/day) and had on average a higher 
body mass index (BMI) (27.1 kg/m2 vs. 26.3 kg/m2) than women, but they more frequently 
reported heavy physical activity (31% vs. 20% > 1 hour/week). Men also had on average a 
higher blood pressure than women (137/84 mmHg vs. 127/79 mmHg). 19% of all participants 
took at least one cardioactive drug (angiotensin converting enzyme inhibitor, anriarrhyhtmic 
drugs class I or III, beta-blockers, calcium channel blockers, diuretics or sympathomimetics), 
5% of the participants took even more than one of those drugs. Almost twice as many 
women than men took diuretics (4.7% vs. 2.4%). Mean level of uric acid in the blood was 325 
μmol/L, of high sensitivity C-reactive protein (hs-CRP) 2.6 mg/L and of non high density 
lipoprotein cholesterol (non-HDL-cholesterol) 4.8 mmol/L. Both uric acid and non-HDL-
cholesterol levels in the blood were significantly higher in men than in women. In a separate 
paper (not included in this thesis), we could also show a higher prevalence of renal 
malfunction in the female population (Nitsch et al. 2006). 
 
Influence of cardiovascular risk factors, biomarkers for cardiovascular health and 
current health status on the results of heart rate variability 
Women showed on average lower HRV. Moreover, increasing age was associated with lower 
HRV. This finding was controversially discussed in the literature so far (Cowan et al. 1994; 
Jensen-Urstad et al. 1997; Stein et al. 1997). This might be due to the fact that ageing curves 
differ between the sexes. We also found lower HRV in subjects with known cardiovascular 
risk factors like smoking, sedentary lifestyle, higher BMI, high blood pressure, high levels of 
uric acid, hs-CRP or non-HDL-cholesterol. Subjects who took beta-blockers also had on 
average lower HRV and HF was elevated in subjects taking antiarrhythmic drugs or beta-
blockers. 
 
SUMMARY   53 
Normal ageing curves for healthy men and women for various HRV measurements 
We calculated normal ageing curves for men and women between 50 and 70 years of age 
who were non-smoking individuals without history of cardiovascular disease, high blood 
pressure or diabetes, and were free of medications. In men, LF/HF values clearly decrease 
between 50 and 70 years of age. In women, such a decrease is only observed after age 60. 
 
5.2 Environmental tobacco smoke 
Longer-term exposure to environmental tobacco smoke reduces heart rate variability 
Subjects who had been exposed to environmental tobacco smoke at home or at work for 
more than two hours per day over the preceding year had a lower 24-hour and night-time 
HRV than subjects not exposed to second-hand smoke in these places. The elevated night-
time values point toward a long-term effect of passive smoking on HRV. 
 
Possible pathways for the reduced heart rate variability in association with exposure 
to environmental tobacco smoke 
In order to test possible pathways of reduced HRV in association with exposure to 
environmental tobacco smoke, we also analysed heart rate and blood pressure. Both heart 
rate and diastolic blood pressure were higher in subjects exposed for more than two hours 
per day at home or at work as opposed to subjects not exposed to tobacco smoke pollution 
in these places. These findings together with the observation of a decreased LF power are 
consistent with increases in sympathetic stimulation. 
 
5.3 Exercise and body mass index 
Regular exercise improves heart rate variability 
In a multivariable regression analysis, obese subjects (BMI ≥ 30 kg/m2) exercising regularly ≥ 
2 hours per week had a 19% higher standard deviation of all normal RR (NN) intervals 
(SDNN) than obese sedentary subjects. Within each BMI category, subjects exercising ≥ 2 
hours per week had higher HRV values than subjects not exercising. Compared with 
subjects who gained weight and did not exercise regularly, those who gained weight but did 
exercise regularly had a 13% higher SDNN. 
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Adverse effects of obesity and weight gain on heart rate variability are modified by 
regular exercise 
Exercising regularly significantly modified the relation of obesity with SDNN. The interplay 
terms between body mass index and ≥ 2 hours per week of physical activity in their effect on 
the natural logarithm of SDNN were all statistically significant. HRV in physically active 
persons did not depend on BMI. 
 
6. General discussion 
 
6.1 Discussion 
In this thesis, we described normal values of HRV for a healthy population, personal and 
environmental determinants of HRV and modification of the effect of obesity as a risk factor 
for lower HRV by exercise, based on a population-based sample of 1742 24-hour ECG 
recordings. 
As HRV is known to be associated with cardiovascular disease risk and mortality, it could 
serve clinically as an early marker for cardiovascular disease. To be an appropriable 
diagnostic tool, population-based reference values are needed (North American Society of 
Pacing and Electrophysiology 1996). Up to the present, such normal values based on large 
samples have not been published, as far as is known. We were able to present age-
dependent percentile curves for 24-hour HRV in a middle-aged to elderly population, 
showing different ageing patterns for men and women. In men between 50 and 70 years of 
age, the ratio between LF and HF decreased linearly, whereas in women such a decline was 
only manifest after the age of 60. 
To our knowledge, we were also the first to show the combined effect of a large variety of 
risk factors on HRV in a normal population. Independent of other risk factors, current 
smoking showed a strong negative effect on HRV. Higher BMI proved to be an independent 
risk factor for lower HRV in our data. This allows speculations on mechanisms and 
observations on the effect of behaviours that are known to improve cardiovascular health 
(Buchheit et al. 2004; Tulppo et al. 2003). 
The main goal of the SAPALDIA study was to look at the effect of air pollution, including 
environmental tobacco smoke, on human health. Results from SAPALDIA about the 
association between ETS and respiratory symptoms (Leuenberger et al. 1994), respiratory 
function (Kunzli et al. 2000) as well as the role of bronchial hyperreactivity in the 
development of respiratory symptoms in subjects exposed to ETS (Gerbase et al. 2006) 
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have been published. In this thesis we looked at the effect of ETS on HRV and at possible 
pathways. We were able to demonstrate that exposure to passive smoking is associated with 
lower HRV, and we showed that not only 24-hour HRV was lower in exposed subjects, but 
also night-time values of HRV, thereby suggesting a longer-term effect of second-hand 
smoke on the autonomic nervous system. To date, the only other study which has been 
published on the association between exposure to ETS and HRV showed acute effects 
(Pope et al. 2001). The distribution of the HRV frequency and a concurrent association 
between exposure to ETS and higher heart rate as well as a tendency for lower blood 
pressure allowed us to draw conclusions on the mechanism of the risk factor on the 
cardiovascular system. 
In a furder step, we then were interested to see if the negative effect of a risk factor could be 
modified by advantageous behaviour. We were able to show that regular exercise improves 
HRV in normal weight, overweight and obese subjects. We also demonstrated that being 
physically active can override the inauspicious effects of obesity on cardiac autonomic 
control and that HRV in physically active persons does not depend on BMI, a finding which 
has not been previously described. 
 
6.2 Limitations 
Causality 
There are several limitations of this study. According to Bradford Hill's considerations of 
causality, exposure must precede illness (Hill 1965). The cross-sectional character of this 
study makes causal inference difficult. However, we know the weight gain in a prospective 
way and our cross-sectional analyses are in line with results from cohort studies where such 
information is available (Gulli et al. 2003; Hirsch et al. 1991; Jurca et al. 2004). 
 
Questionnaire data 
Some risk factors which have been used in this study were assessed in the interview. This 
makes the information less reliable than if measured in a less subjective way. This problem is 
most obvious for physical activity, which has been assessed by four different questions. 
Those questions have been validated (Washburn et al. 1990) and already been used in other 
studies (The European Community Respiratory Health Survey II 2000). In addition, we have 
data on physical activity from the time activity diary for validation (data not yet appropriable). 
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Measurements 
Because the interpretation of HRV is to a high degree dependent on the study population 
and the circumstances of recording, comparability with other studies is limited. 
If in future HRV should also clinically be used as a marker of cardiovascular health, we also 
have to be alert to several difficulties. Its measurement requires normal sinus rhythm and 
reasonable signal quality. In patients with atrial fibrillation, sinoatrial dysfunction, and >20% 
ectopic complexes its use is precluded (Kleiger et al. 2005), whereas in the normal 
population such arrhythmias are not very frequent (Aronow 2006). Signal quality and 
elimination of background noise requires great care in the preparation of the skin and the 
applying of the electrodes. Careful editing of the recording is necessary to exclude ectopic 
complexes and artifacts from the calculations and clinical scanning is not usually adequate 
for detailed HRV analysis. The best predictors of cardiovascular mortality require rather long 
recording periods in order to include both night-time and day-time periods, inducing a 
considerable amount of work for the editing. 
Another problem when measuring HRV is of accurately locating the successive R-wave 
peaks on the ECG. This requires a robust R-wave detector algorithm. The more accurate the 
R-wave detector, the less error in the analysed HRV spectrum. A completely missed R wave 
will cause greater error than a slightly miscorrected R wave, and this error is reflected more 
in the HF than in the LF of the HRV spectrum (Reed et al. 2005).  
 
HRV variables 
Although research has made considerable advances in the field, it is still unclear as to which 
HRV variable suits best as a predictor for cardiovascular mortality; conventional time domain, 
baroreflex sensitivity, heart rate turbulence, spectral measures, geometric measures, and a 
variety of nonlinear variables reflect different aspects of HRV and have all been significantly 
associated with outcome without clear, consistent superiority for any of the variables (Kleiger 
et al. 2005). 
 
6.3 Strengths 
A major strength of this study was the large number of participants, who were a random 
selection of the population aged ≥ 50 of eight different areas of Switzerland. To our 
knowledge, no other study has presented 24-hour HRV results from a population-based 
sample of this size. The collected data allowed us to detect sex differences in the age-related 
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decline of HRV and to study independent associations of a variety of cardiovascular risk 
factors with HRV. 
 
6.4 Outlook 
Implications for public health practice 
This study adds to the evidence of desirable or disadvantageous effects of different factors 
on cardiovascular health. The implications from the described results for public health 
practice should be to develop or pursue strategies of cardiovascular prevention, i.e. among 
other things prevention of tobacco smoke exposure, of obesity and of sedentary lifestyle, 
especially in obese persons. Public health policies must focus on prevention of all major risk 
factors simultaneously, using lifestyle approaches from early ages onwards to reduce 
population cardiovascular risk. The prevention strategies should aim to be effective on 
different levels, from primordial over primary and secondary to tertiary on an individual as 
well as on a community level. Primordial prevention, i.e. social, legal and other activities 
which may lead to a lowering of risk factors, seems to be especially suited for the prevention 
of exposure to environmental tobacco smoke. Non-smokers should be prevented from 
exposure to ETS, if necessary by legal ways. Ticino was the first canton in Switzerland to 
adopt a law for smoke-free restaurants, which will come into force in April 2007. A scientific 
evaluation of the health consequences of the affected persons would bring more insight into 
topics discussed in this thesis. The implementation of such laws might also lead to a 
decrease in active smoking, another important risk factor of cardiovascular disease. 
HRV might in future play a role in cardiovascular disease risk stratification of the 
asymptomatic population for targeted prevention. As stated in the guidelines for prevention 
by the World Heart and Stroke Forum, a combination of risk factors should be considered for 
assessing total CVD risk (Smith et al. 2004). Several tools have been developed for risk 
estimation, most of which are derived from the Framingham Study (Anderson et al. 1991; 
D'Agostino et al. 2000; Wilson et al. 1998). HRV could be a measure which, in addition to 
traditional cardiovascular risk factors, helps to identify subjects for which primary prevention 
is especially effective. Since HRV is influenced over pathways involving the autonomic 
nervous system, it can be speculated that in subjects with low HRV, preventive measures 
should aim at improving the autonomic balance. Further research is needed to answer these 
questions. 
HRV measurements could be an eligible tool for secondary cardiovascular prevention, i.e. 
screening of symptomatic patients, and for the control of the success of tertiary prevention. It 
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could also serve to detect those at greatest risk (individual approach) and to determine the 
effectiveness of prevention programs. 
 
Outlook for public health research 
The original and main reason for SAPALDIA was to study the consequences of exposure to 
air pollution on human health. This question is still unanswered for cardiovascular health. A 
next step will be to look at the effect of exposure to different air pollutants on HRV. In this 
context, there are further questions which are of interest, for example the association of 
polymorphisms in blood coagulation genes and HRV, and their interaction with air pollution. 
As mentioned in the discussion, the present work has a cross-sectional design. In order to be 
able to answer the question of causality, a further follow-up study is needed. In this follow-up 
study, the following research questions could perhaps be answered: 
- Is HRV usable as an early marker of cardiovascular health in the normal Swiss 
population? 
- Which other cardiovascular risk factors have to be considered for a risk stratification 
of the asymptomatic population? 
- Which part of cardiovascular risk is explained by HRV and which part by other risk 
factors? 
- What is the influence of longer-term exposure to environmental risk factors on HRV? 
- Is there a modification of the effect of longer-term exposure to environmental risk 
factors on HRV by genetic markers? 
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8. Appendices 
8.1 Instructions for fieldworkers 
8.1.1 Standard operating procedure for the ECG recording 
 
1. Ziel: 
Das Ziel dieser Untersuchung ist eine kontinuierliche Aufzeichnung der Herzstromkurve während 
mindestens 20 Stunden.  
 
2. Information für Fieldworker: 
Die Aufzeichnungen werden an unseren Partner in Frankreich (Dr. JC Barthélémy, Université de St-
Etienne) gesandt, welcher die Analyse der Herzrhythmusvariabilität und von ST-Segment-Senkungen 
vornimmt. 
 
3. Informationen für Probanden: 
Die Probanden erhalten ein Informationsblatt mit den wichtigen Informationen (siehe Anhang). 
Die Probanden dürfen während der 20-stündigen EKG-Aufzeichnung bis auf Duschen, Baden oder 
Sauna alle Aktivitäten ausüben; sie sollen ihrem normalen Tagesablauf nachgehen. Es ist wichtig, 
dass die Probanden nur im Notfall (z.B. bei allergischer Reaktion auf die Elektroden) das EKG vor 
Ablauf der 20 Stunden abnehmen. 
 
4. Aus- und Einschlusskriterien: 
Ausschlusskriterien: 
- Träger von Herzschrittmachern 
- Narkose oder Spinalanästhesie innerhalb der vergangenen 8 Tage 
- Probanden und Probandinnen, welche jünger als 50 Jahre alt sind (Einschluss ab dem 50. 
Geburtstag) 
 
 
5. Vorbereitung: 
1. Ableitungskabel aus dem EKG-Rekorder ziehen 
2. Kartonschachtel für den Rückversand bereit machen 
 mit CHF 3.60 frankieren 
 mit „A Priority“ kennzeichnen 
 Adressettikette prüfen 
 Ersatzelektroden, Klebstreifen und Polstermaterial in die Schachtel legen 
3. Tasche für das Tragen des EKG Rekorders um den Hals aus TubeGaze vorbereiten 
 
6. Untersuchungsablauf: 
1. Die Elektroden werden nach der Blutentnahme befestigt. 
2. Der Proband soll auf der Untersuchungsliege liegen und den Oberkörper entkleidet haben 
(auch BH). 
3. Auffinden der vier Stellen, wo die Elektroden befestigt werden, durch genaue Palpation. Die 
rote und orange Elektrode sollen möglichst auf der untersten Rippe zu liegen kommen. Falls 
jedoch durch Kleidungsstücke (z.B. Hosenbund) Aufzeichnungsstörungen verursacht werden 
können, müssen diese Elektroden auf einer Rippe weiter kranial platziert werden.* 
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4. Sehr gründliches Reinigen der Haut an den 4 Stellen mit einem Alkoholtupfer. 
5. Rasieren eines kleinen Areals über den vier Stellen falls nötig. 
6. Abwischen der Haut mit trockener Gaze 
7. Aufkleben der Elektroden an den entsprechenden Stellen. Nicht auf das Zentrum der 
Elektrode drücken, da sonst der Kontaktgel unter die Klebefläche quillt. 
8. Anschliessen der Ableitungen gemäss Schema. 
9. Ableitungskabel gemäss Farbcode fest in den EKG-Rekorder einstecken. 
10. Ankleben der Ableitungen, damit Bewegungen des Probanden möglichst keine Störungen bei 
der Aufzeichnungen verursachen. 
11. Einlegen der Batterie ins Batteriefach des Rekorders. Es ertönt ein Piepston. 
12. Langes Drücken auf den Knopf mit dem Herz-Symbol bis mehrere kurze Piepstöne und ein 
langer Piepston zu hören sind. Damit beginnt die EKG-Aufzeichnung. 
13. Einlegen des Rekorders in die Tasche und Umlegen um den Hals 
14. Notieren der Rekorder-Nummer auf dem Tagebuch und der Startzeit auf dem Laufblatt 
15. Notieren der Zeit auf dem Tagebuch, wann das Gerät frühestens entfernt werden darf (= 
aktuelle Zeit + 20 Stunden; aufrunden auf nächste volle Viertelstunde) 
16. Erklären von Tagebuch und Fragebogen. Abmachen mit der Probandin/dem Probanden, ob 
sie das Gerät selbst entfernen oder ob sie dafür ins Zentrum kommen wollen. 
 
Entfernen des Rekorders 
1. Entfernen der Batterie aus dem Rekorder. Die Batterie reicht nur für eine Aufnahme und soll 
sofort in die Recycling-Box geworfen werden (Ausnahme bei Verwendung von 
wiederaufladbaren Akkus), damit sie nicht fälschlicherweise nochmals gebraucht wird. 
2. Notieren der genauen Zeit auf dem Laufblatt 
3. Vorsichtiges Entfernen der Klebestreifen 
4. Lösen der Ableitungen von den Elektroden 
5. Lösen der Elektroden von der Haut. Die Elektroden werden nach einmaligem Gebrauch 
weggeworfen. 
6. Reinigen der Haut von Kleb- oder Kontaktgelrückständen 
7. Reinigung des Gerätes und der Ableitungen mit Desinfektionsmittel, wobei kein 
Desinfektionsmittel in das Gerät gelangen darf 
8. Bei Verwendung von Akkus Wiederaufladen derselben 
 
7. Rückgabe: 
1. Überprüfen, ob die Rückgabe komplett ist: Rekorder mit 4 Ableitungskabeln, Tagebuch 
ausgefüllt, Kardio-Fragebogen ausgefüllt, wiederaufladbarer Akku 
2. Überprüfen, ob Batterie/Akku aus dem Gerät entfernt wurde 
3. Reinigung des Gerätes und der Ableitungen mit Desinfektionsmittel, wobei kein 
Desinfektionsmittel in das Gerät gelangen darf 
Die Kartonschachtel, in der die Rückgabe erfolgt, kann mehrmals verwendet werden. 
Weiss: Mitte des Manubriums 
Rot:  linke vordere Axillarlinie, auf der 
untersten Rippe* 
Braun: 2 cm rechts des Processus 
xyphoideus am Rippenrand 
Orange: Medioclavicularlinie, auf der 
untersten Rippe* 
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8. Laden der Daten auf den Computer: 
1. Wahl von Windows 98 beim Aufstarten des PCs 
2. Doppelklicken auf dem Desktop auf das Icon HOLTER 98 
3. Drücken der Taste „F2“ oder Klicken auf „F2 NEUER PAT.“. 
4. Eingeben der Probanden-Nummer (z.B. 9999/160) bei NAME, REPORT NUMMER und ID #. 
5. Eingeben der Startzeit der EKG-Aufzeichnung bei START TIME, des Anfangsdatums bei 
TEST DATE, des aktuellen Datums bei REPORT DATE, des Alters, des Geschlechts bei SEX 
(weiblich: f; männlich: m), der Fieldworker-Nummer (z.B. 160/02) bei PHYSICIAN und wählen 
von ARIA bei RECORDER TYPE. 
6. "ESC" und danach "YES" wählen 
7. Entfernen der Ableitungen durch senkrechtes Ziehen an den farbigen Steckern. 
8. Einstecken des Downloadkabels in den Rekorder. 
9. Wieder am PC: markieren des gewünschten Probanden durch anklicken. Als Hintergrund 
erscheint ein blauer Balken. 
10. Drücken der Taste „F3“ oder auf „F3 LADEN“ drücken. 
11. Wenn das rote Fenster „ECG Data Download Aria Recorder“ erscheint, die Taste “ESC” 
drücken 
12. Beim nächsten Fenster „1“ wählen 
13. Beim nächsten Fenster mit „Y“ bestätigen. Der Download beginnt 
14. Kontrollieren, ob beim entsprechenden Probanden bei Status „LAD“ steht. Falls das nicht der 
Fall ist, ist ein Fehler unterlaufen. In diesem Fall nochmals Punkte 8 bis 13 wiederholen. 
15. zum Verlassen des Programmes dürfen keine Patienten ausgewählt sein (kein hellblauer 
Balken). 
15.1 „F8“ 
15.2 „Exit to Desktop“ anklicken 
15.3 Bestätigen mit „j“ 
16 Einstecken der Ableitungen in den Rekorder gemäss Farbcode. 
 
Überspielen der Daten auf CD-ROM 
17 Die EKG-Aufzeichnungen werden 1x wöchentlich auf einen CD-Rohling überspielt und ans ISPM 
Basel gesandt. 
18 Wahl von Windows 98 beim Aufstarten des PCs 
19 Einlegen einer unbeschriebenen CD in das CD-Laufwerk 
20 Formatieren der CD-R 
20.1 im Fenster von directCD „CD formatieren“ wählen 
20.2 im Fenster "Kennung" CD mit Ort und aktuellem Datum benennen (z.B. "Basel 121101" für 
eine CD, welche am 12.11.01 in Basel gebrannt wurde) 
20.3 auf „Formatierung beginnen“ klicken 
20.4 im Fenster „CD bereit“ auf „OK“ klicken 
21 Auf dem Desktop auf „Holter98“ doppelklicken 
22 Drücken der Taste „F8“ oder „F8 EXIT“ anklicken 
23 „Build Optical Disk“ wählen 
24 mit “ESC” zurück zur Patientenauswahl 
25 Auswählen der Daten, welche kopiert werden sollen durch anklicken der entsprechenden Zeile 
(Auswahl wird durch hellblauen Hintergrund markiert) 
26 „ALT" drücken und ohne loszulassen "F8" drücken: Die Daten werden auf CD gebrannt 
27 zum Verlassen des Programmes dürfen keine Patienten ausgewählt sein (kein hellblauer Balken). 
27.1 „F8“ 
27.2 „Exit to Desktop“ anklicken 
27.3 Bestätigen mit „j“ 
28 Beim Auswurf der CD erscheint ein Dialogfeld: „unverändert lassen“ wählen 
 
 
9. Resultate 
 
Die Probanden erhalten in der Regel ca. 4 Wochen nach der Untersuchung ihre Resultate schriftlich 
(Vgl. Anhang „Probandeninformation“). Falls jedoch ein gravierender pathologischer Befund entdeckt 
würde, werden sie schnellstmöglich informiert. 
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8.1.2 Standard operating procedure for the measurement of blood pressure 
 
1. Ziel: Zweimaliges Messen des systolischen und des diastolischen Blutdruckes in Ruhe. 
 
2. Information für Fieldworker: 
Der OMRON 705CP ist ein vollautomatisches Blutdruckmessgerät, welches mit der oszillometrischen 
Methode misst. Nach dem Aufpumpen der Manschette bis zum Verschluss der Arteria brachialis wird 
der Druck automatisch kontinuierlich verringert. Mit sinkendem Manschettendruck öffnet sich die 
Arterie, wobei sich Druckschwankungen verstärken, welche schliesslich wieder auf kleinere 
Oszillationsamplituden abfallen. Diese Schwingungen werden vom Gerät registriert und der 
systolische und diastolische Wert daraus errechnet1
Gemäss WHO sollten die Blutdruckwerte idealerweise < 120/80 mmHg liegen. Normaler Blutdruck 
wird mit Werten < 130/85 mmHg definiert, Hypertonie mit Blutdruckwerten > 140/90 mmHg. Weil der 
Blutdruck grossen Schwankungen unterliegt, sollte die Diagnose „Hypertonie“ erst nach wiederholten 
Messungen gestellt werden
. 
2
Zeitpunkt der Untersuchung 
. 
Eine Internetsite der WHO liefert gute Hintergrundinformation zum Thema Hypertonie: 
http://www.who.int/ncd/cvd/PracticeGuidelinesSlideset2/index.htm 
 
3. Information für Probanden: 
In einigen internationalen Studien wurden Hinweise für einen Zusammenhang zwischen 
Luftverschmutzung und Gesundheit von Herz und Kreislauf gefunden. In SAPALDIA 2 messen wir 
unter anderem den Blutdruck, um solche Zusammenhänge zu erforschen. 
 
 
4. Aus- und Einschlusskriterien 
 
Einschlusskriterien: 
Der Blutdruck wird bei allen Probanden gemessen. 
 
 
5. Vorbereitung: 
 
Die Blutdruckmessungen finden nach dem Interview statt. (Der Proband muss mindestens 10 Minuten 
gesessen haben und sich an die Umgebung gewöhnt haben. Idealerweise findet die Blutentnahme 
nicht vor dieser Messung statt.) 
 
1. Messung am nackten Oberarm links 
(Ausnahme: Strahlentherapie oder Lymphknotenausräumung in der Axilla z.B. nach Mamma-
Carcinom, Shunt am linken Arm bei Dialysepatienten, Lähmung oder Kontrakturen am linken 
Arm: Vermerk „rechts“ unter Problem-Feld). 
Hochgekrempelte Bekleidung darf den Arm nicht einschnüren. Allenfalls ist die Messung über 
einem dünnen Kleidungsstück möglich. 
2. Der Proband soll bequem sitzen und den linken Arm so auf dem Tisch aufstützen (eventuell 
mit Kissen), dass sich die Ellenbeuge auf Herzhöhe (vierter Interkostalraum) befindet. 
3. Messen des Oberarmumfanges links an der dicksten Stelle mit dem Massband. 
Umfang 22-32 cm: Standardmanschette / Umfang 32-42 cm: extragrosse Manschette 
(protokollieren bei Verwenden der extragrossen Manschette bei „Probleme“). 
4. Einschalten des Blutdruckmessgerätes (Taste „O/I) 
Es leuchten alle Symbole auf der Anzeige während etwa 2 Sekunden, was zur Überprüfung 
der Anzeige dient. Dann erlöschen alle Symbole, und das Luftablass-Symbol () beginnt zu 
blinken. Wenn die Messvorbereitungen abgeschlossen sind, erscheint das Messbereitschafts-
Symbol (♥) auf der Anzeige. 
 
6. Untersuchungsablauf: 
                                                 
1 Gebrauchsanweisung OMRON 705CP. 
2 http://www.who.int/ncd/cvd/PracticeGuidelinesSlideset2/index.htm 
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1. Manschette so am linken Oberarm anlegen, dass Unterkante 2-3 cm oberhalb der Ellenbeuge 
liegt und sich die grüne Markierung über der Arteria brachialis befindet. Die Manschette soll 
satt anliegen aber den Arm nicht einschnüren. 
2. Der Proband wird aufgefordert, während der Messung nicht zu sprechen und sich nicht zu 
bewegen. 
3. Drücken der Start-Taste (). 
Das Gerät pumpt nun automatisch bis zum Erreichen des gewählten Druckwertes auf (erweist 
sich der eingestellte Wert als nicht ausreichend, pumpt das Gerät automatisch weiter auf, bis 
der Druck für die Messung ausreicht), wonach die Luft aus der Manschette automatisch 
abgelassen wird. Das Druckabfall-Symbol () zeigt den Entlüftungsvorgang an. Sobald der 
Pulsschlag erkannt ist, beginnt das Symbol (♥) zu blinken, und gleichzeitig ertönt ein Piepen. 
Wenn die Luft vollständig entwichen ist, erscheint das Symbol (♥) auf der Anzeige, und es 
werden Blutdruck und Puls abwechselnd ca. 5 Minuten lang angezeigt. 
4. Ausdrucken der Messwerte durch drücken der Taste „P“ 
5. Wiederholung der Punkte 7.-9. nach mindestens 3 Minuten. 
Idealerweise sollten die Messungen nicht viel länger als 3 Minuten auseinander liegen. Die 
Messzeiten sind auf dem Ausdruck ersichtlich. 
6. Aufkleben der ausgedruckten Resultate auf die vorgesehene Stelle auf dem Laufblatt. 
7. Nochmaliges Ausdrucken der letzten Messwerte, zusammen mit dem Blatt 
„Blutdruckmessung“ dem Probanden mitgeben. 
 
7. Qualitätskriterien: 
Errormeldung: 
Falls bei einer Messung eine Errormeldung erscheint, Messung nach mindestens 3 Minuten 
wiederholen. 
- Falls nach 2 Versuchen keine Messung erfolgreich war, durch Palpation des Pulses 
überprüfen, ob eine Arrhythmie vorliegt. Bei Bestätigung einer Arrhythmie Eintrag „Arrhythmie“ 
unter Probleme und Information des Probanden (Empfehlung einer Konsultation beim 
Hausarzt, falls Problem nicht schon bekannt ist). 
- Bei Wiederholung der Messung wegen Errormeldung Vermerk unter Probleme, z.B. „1. 
Messung Errormeldung“ 
 
„Unwahrscheinliche“ Messresultate 
Der Blutdruck unterliegt einer grossen Variabilität, auch wenn zwei Messungen innerhalb von nur 
einigen Minuten erfolgen. (Varianz bei zwei Messungen innerhalb von 5 Minuten: 26.5 mm2Hg beim 
systolischen Blutdruck, 11.8 mm2Hg beim diastolischen3
- Wurde die richtige Manschettengrösse verwendet? 
). 
 
Falls die Messwerte in einem „unwahrscheinlichen“ Bereich liegen (Proband sagt zum Beispiel, dass 
er sonst ganz andere Blutdruckwerte habe): 
- Liegt eine Arrhythmie vor (vgl. oben)? 
 
Es werden immer nur die zwei ersten Messergebnisse nach korrekter Messung an das Laufblatt 
geheftet. Falls aus irgendeinem Grund (wenn z.B. der Proband beunruhigt ist und eine zusätzliche 
Messung wünscht) eine dritte Messung erfolgt, wird dieses Resultat nicht zu den Unterlagen 
genommen. 
 
Bei anderen Problemen mit dem Gerät die Gebrauchsanleitung konsultieren. 
Lieferant: Advance AG, Wädenswil: 01 782 68 78 
 
 
Qualitätskontrolle 
Die verschiedenen Geräte sind nummeriert und die Studienleitung hat die Übersicht über den Standort 
und Prüfstatus der einzelnen Geräte. 
Die Geräte wurden vor dem 1. Gebrauch auf ihre Genauigkeit geprüft. Diese Prüfung wird im Laufe 
der Studie wiederholt, wobei das Untersuchungszentrum eine Aufforderung erhält, das zu prüfende 
                                                 
3 Klungel OH, de Boer A, Paes AHP, Nagelkerke NJD, Seidell JC, Bakker A. Estimating the prevalence of 
hypertension corrected for the effect of within-person variability in blood pressure. Journal of Clinical 
Epidemiology 2000; 53: 1158-63. 
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Gerät einzusenden und für diese Zeit ein Ersatzgerät erhält. Bei Verwenden des Ersatzgerätes auf 
dem Papierstreifen mit den Resultaten Gerätenummer notieren. 
 
 
8. Datentransfer 
 
 
Anhang 
 
Inbetriebnahme des Blutdruckmessgerätes: 
1. Anschliessen des Messgerätes an Stromquelle mit Netzteil (separates Zubehör). 
2. Einstellen von Uhrzeit und Datum: 
 Drücken der Taste „TM“. Die Anzeige des Monats beginnt zu blinken. 
 Mehrfaches drücken der Taste „TS“ zur Einstellung des aktuellen Monats. 
 Drücken der Taste „TM“. Die „TAGES“-Zeichen beginnt zu blinken. 
 Mehrfaches Drücken der Taste „TS“ zur Einstellung des Tages. 
 Drücken der Taste „TM“. Die Anzeige von Stunden und Minuten beginnt zu blinken. 
 Mehrfaches drücken der Taste „TS“ zur Einstellung der aktuellen Zeit. 
 Drücken der Taste „TM“. 
 Kontrollieren von Datum und Uhrzeit: AM = vormittags (0-12 Uhr), PM = nachmittags (12-24 Uhr). 
Erneute Kontrolle zu Beginn jeder Woche (Achtung: Wechsel Sommer-/Winterzeit!) 
3. Druckerpapier einlegen 
 Entfernen des Klebestreifens von der Rolle und Geradeschneiden des Papierendes mit einer 
Schere. 
 Einführen des Papierstreifenendes in den Papierschlitz. 
 Drücken Sie der Papiertransporttaste „PF“ und Herausführen des Papiers bei der Abrisskante. 
 Einlegen der Papierrolle in das Fach. 
 Durch die Öffnung im Druckerdeckel ziehen des Streifens und Schliessen des Druckerdeckels. 
Einstellen Druckvorwahlschalter auf 170 mmHg. 
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8.2 Procedure for analyses of electrocardiograms 
 
by Jean-Claude Barthélémy and Frédéric Roche, Université Jean Monnet, Saint-Etienne, 
France, 2004 
 
Standard 24-hour Holter Monitoring 
Standard 3-channel Aria® ECG Holter recorders were used to acquire the data (Del Mar, 
Irvine, CA). All recordings were scanned through a StrataScan 563 (Del Mar) and read using 
the interactive method, followed by a final visual check of the full disclosure. The 
electrocardiographic Holter system allowed to extract the list of RR intervals with a precision 
of 1/128 second. The length of each RR interval was manually validated during this step. 
 
Arrhythmia analysis: 
- Pauses. An R-R interval was considered to be a pause when it reached or exceeded 
3.5 seconds. 
- Bradycardia. Bradycardia was defined as a rhythm below 40 beats per minute. 
- Ventricular ectopic activity. Isolated and grouped ventricular ectopic activities were 
analysed. Non-sustained ventricular tachycardia was defined as 3 or more 
consecutive ventricular ectopic complexes, at a rate faster than 120 beats per minute 
and lasting less than 30 seconds. The severity of ventricular arrhythmias was 
evaluated by the mean number of ventricular premature complexes (VPCs) per hour 
(threshold value : „ 30/h). 
- Supraventricular ectopic activity. Isolated and grouped supraventricular ectopic 
activities were analyzed separately. Supraventricular tachycardia (SVT) was defined 
as more than 6 consecutive supraventricular ectopic complexes, at a rate higher than 
120 beats per minute. Sustained SVT was defined as more than 30 seconds of 
supraventricular ectopic complexes at a rate faster than 120 beats per minute. 
 
Three recording periods were defined: a "nocturnal" period, a "diurnal" period and "full 
recording" period from the beginning to the end of the recording. 
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Heart rate variability analysis 
Time Domain Analysis:  
The r-MSSD (root mean square successive differences, the square root of the mean of the 
sum of the squares differences between adjacent normal RR intervals) and pNN50 (percent 
of adjacent normal RR intervals which differ by more than 50 msec computed over the entire 
recording) indices were considered as the parasympathetic tone component. The SDNN 
(standard deviation of all normal RR intervals in the entire recording), SDANN (standard 
deviation of the mean of all 5-minute segments of the normal RR intervals) and SD Index 
(mean of the standard deviations of all normal intervals for all the 5-minutes segments of the 
all ECG recordings) indices were also computed. 
 
Frequency Domain Analysis:  
Spectral analysis was performed by the Fast Fourier Transform method using sliding 256 
PTAs Hanning windows. Only normal-to-normal intervals were used, with intervals excluded 
due to ectopy or artefacts being replaced by holding the previous coupling interval level 
throughout the time interval to the next valid coupling interval 
Power spectrum indices were calculated as recommended by the Task Force of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. The high frequency peak of the spectrum (HF, 0.15 to 0.40 Hz) is known 
to represent parasympathetic activity, while the low frequency (0.04 to 0.15 Hz) represents 
both parasympathetic and sympathetic activities. Additional calculations were included: the 
very low frequency power (0 to 0.04 Hz); the ratio LF/HF, which represents an evaluation of 
the autonomic nervous system balance (sympathetic/parasympathetic); the normalized low 
and high frequency power (LF nu and HF nu) as 100*LF/(total power - VLF) and 
100*HF/(total power - VLF), respectively; and the total frequency power (Ptot). 
 
Wavelet Transform: 
Then, autonomous nervous system activity was evaluated using time-frequency analysis of 
the RR variability signal. This method and the meaning of the usual indices have been 
described and validated in published studies. 
Unlike Fourier, Wavelet transform is devoted to the analysis of non-stationary signal. Thus, 
there is no prerequisite regarding the stability of the frequency content along the signal 
analysed. This analysis is devoted to the extraction of characteristic frequencies, contained 
along a signal which, in this case, was composed by consecutive intervals between RR 
interval series. The decomposition  of a signal by Wavelet transform requires a function 
adequately regular and localised, named Mother function. Starting from this initial function, a 
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family of functions is built by dilatation and translocation, which constitutes the so-called 
Wavelet frame. 
The analysis amounts to sliding a window of different weights (corresponding to different 
levels) containing the Wavelet function, all along the signal. The calculation gives a serial list 
of coefficients named Wavelet coefficients, which represent the evolution of the correlation 
between the signal f and the chosen Wavelet at different levels of analysis (or different 
ranges of frequencies) all along the signal f. 
In the present analysis, we used the Daubechies 4 Wavelet transform. For each record, the 
Wavelet coefficients were calculated on sets of 256 RR intervals, giving seven separate 
levels of analysis named 2, 4, 8 ... 128. Then, we calculated the variability power, level by 
level, as the sum of squares of the coefficients. Thus, we obtained, for each recordings, the 
variability power for each level. 
The sum of Wavelet power coefficients at levels 2, 4 and 8 (HFWavelet), approximately 
corresponds to the Fourier High Frequencies (an index of parasympathetic activity); Wavelet 
power coefficients at levels 16 and 32 (LFWavelet) roughly  corresponds to the Fourier Low 
Frequencies; Wavelet power coefficients at levels 64 and 128 (VLFWavelet) to the Fourier 
Very Low Frequencies; and the ratio LFWavelet/HFWavelet to the Fourier ratio.  
Pertinent HRV variables for the autonomic status were calculated for daytime, night-time and 
full recording periods. 
APPENDICES   75 
8.3 Results of simultaneous ECG recordings 
 
Table of one-way analysis of variance for the simultaneous recordings (n=20) 
Variable Standard deviation of participant effect 
Standard deviation of 
measurement error Intraclasscorrelation 
SDNN 41.4  3.6  0.996  
Total Power 1236.8  597.7  0.895  
HF 83.3  8.1  0.995  
LF 244.9  8.0  1.000  
VLF 178.1  12.5  0.998  
ULF 2450.4  604.2  0.971  
 
8.4 Results of double ECG analyses 
 
Table of one-way analysis of variance for the double recordings (n=9) 
Variable Standard deviation of participant effect 
Standard deviation of 
measurement error Intraclasscorrelation 
SDNN (24h) 26.7  0.5  1.000  
SDNN (day) 25.9  4.6  0.984  
SDNN (night) 23.0  10.7  0.903  
Total Power (24h) 2277.9  59.3  1.000  
Total Power (day) 509.0  98.5  0.981  
Total Power (night) 648.7  185.4  0.961  
HF (24h) 31.4  8.7  0.963  
HF (day) 30.5  13.7  0.908  
HF (night) 64.5  10.8  0.986  
LF (24h) 104.6  3.8  0.999  
LF (day) 125.2  11.1  0.996  
LF (night) 115.5  19.7  0.986  
VLF (24h) 342.8  9.6  1.000  
VLF (day) 400.9  68.7  0.986  
VLF (night) 498.1  160.5  0.951  
ULF (24h) 1948.9  43.1  1.000  
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8.5 Time activity diary 
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Langzeit-EKG 
 
Fragebogen und Tagebuch 
 
 
 
 
    
 
 
 
 
 
 
 
Recorder-Nr.: _______________________ 
 
 
 
 
 
 
 
 
 
Ende frühestens ________________________ 
 
Information 
 
Das Elektrokardiogramm (EKG) 
Der EKG-Rekorder zeichnet den elektrischen Strom auf, welcher im Herzen generiert wird. Dieser Strom ist dafür verantwortlich, dass 
sich die Herzmuskulatur rhythmisch zusammenzieht und somit das Blut zirkulieren lässt. 
 
Das Langzeit-EKG (Holter-EKG) 
Das Langzeit-EKG wird üblicherweise verwendet, um Herzrhythmusstörungen oder Durchblutungsstörungen des Herzmuskels zu 
erkennen, wenn ein Verdacht auf eine solche Krankheit vorliegt. In SAPALDIA 2 zeichnen wir die Herzstromkurve während 20 
Stunden auf und beurteilen anschliessend den Herzrhythmus sowie dessen Variabilität und wir suchen nach Anzeichen einer 
Durchblutungsstörung im Herzen. Diese Analysen werden von unserem Forschungspartner in Frankreich, einem Spezialisten auf dem 
Gebiet der Herz- und Lungenphysiologie, gemacht, weshalb Sie im Normalfall ungefähr 4 Wochen warten müssen, bevor Sie von uns 
das Resultat dieser Untersuchung erhalten. 
 
Was Sie während der EKG-Aufzeichnung beachten müssen 
Sie dürfen während der EKG-Aufzeichnung Ihrem gewohnten Tagesablauf nachgehen – einzig das Baden oder Duschen müssen Sie 
während dieser Zeit unterlassen. Behalten Sie während der Nacht das Gerät in der Tragetasche um den Hals. 
 
Wie Sie das Gerät selber abstellen und entfernen 
Falls wir mit Ihnen vereinbart haben, dass Sie das Gerät selber entfernen, gehen Sie bitte nach der auf dem Tagebuch notierten Zeit 
so vor: 
 
1. Nehmen Sie das Gerät aus dem Umhängebeutel und entfernen Sie die Batterie aus dem Batteriefach auf der Rückseite 
des Gerätes (Öffnen des Batteriefaches durch Schieben des Deckels nach links). 
2. Schreiben Sie die Zeit auf das Tagebuch. 
3. Entfernen Sie die Klebestreifen. 
4. Lösen Sie vorsichtig die farbigen Druckknöpfe von den auf die Haut geklebten Elektroden. Lassen Sie die 
Ableitungskabel im Gerät stecken. 
5. Lösen Sie die Elektroden von Ihrer Haut. Sie können die Elektroden wegwerfen. 
6. Reinigen Sie Ihre Haut gründlich aber sanft. Das Auftragen einer milden Körperlotion kann helfen, einen Juckreiz zu 
verhindern oder zu lindern. 
7. Bringen Sie uns Gerät, Kabel und Batterie zurück oder senden sie es uns im frankierten und adressierten Karton 
möglichst rasch zurück. 
 
Unvorhergesehene Fälle 
- Falls sich eine Elektrode von der Haut löst, was bei starkem Schwitzen vorkommen kann, kleben Sie eine neue 
Elektrode aus dem Notfallset auf dieselbe Stelle und befestigen Sie das Ableitungskabel an der Elektrode. 
- Falls sich ein Ableitungskabel von der Elektrode löst, so bringen Sie dieses wieder an. 
- In seltenen Fällen kann es vorkommen, dass die Haut allergisch auf die Klebestreifen reagiert. Entfernen Sie in 
diesem Fall das Gerät, indem Sie wie oben beschrieben (Punkt 1. bis 7.) vorgehen. Die Haut kann in einem solchen Fall 
mehrere Tage gerötet sein und jucken. 
 
Legen Sie die Batterie keinesfalls wieder in das Gerät ein, wenn sie einmal entfernt 
wurde oder heraus fiel! 
Hier Etikette mit 
Probanden-ID 
aufkleben 
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1. Teil Fragebogen 
 
 
 
Bitte beantworten Sie die ersten 3 Fragen möglichst rasch. 
 
Wie viele Tassen Kaffe haben Sie während den 4 Stunden vor der EKG-Untersuchung getrunken? 
 
 
_ _ Tassen 
Wie viele Tassen Schwarz- oder Grüntee haben Sie während den 4 Stunden vor der EKG-Untersuchung 
getrunken? 
 
 
_ _ Tassen 
Wie viele Gläser Alkohol haben Sie während den 24 Stunden vor der EKG-Untersuchung getrunken? 
 
 
_ _ Gläser 
 
 
 
 
Leiden Sie an folgender Krankheit, hatten Sie folgende Operation? 
 
Ja Nein 
• Herztransplantation   
• Sudeck’sche Krankheit (Algodystrophie, sympathische Reflexdystrophie, 
komplexes regionales Schmerzsyndrom) 
  
• hyperreaktiver Karotissinus-Reflex   
• Amyloidose   
• Kollagenose   
• Schilddrüsenüberfunktion (Hyperthyreose, Thyreotoxikose)    
• Leberzirrhose oder hepatozelluläre Insuffizienz    
• Anorexia nervosa (Magersucht) oder andere Ernährungsverhaltensstörungen 
(Bulimie) 
  
• HIV-Infektion (AIDS)    
Hatten Sie im vergangenen Monat gelegentlich das Gefühl eines unregelmässigen Herzrhythmus?   
Hatten Sie in den vergangenen 8 Tagen eine Narkose (Allgemeinanästhesie) oder eine Spinalanästhesie 
(durch Injektion in den Rückenmarkskanal)?  
 
 
 
 
Haben Sie zur Zeit eine Sauerstofftherapie?   
Konsumieren Sie Kokain?   
 
 
Anleitung zum Tagebuch 
 
Anleitung: 
 
Was Sie beachten sollten, bevor Sie das Tagebuch auszufüllen beginnen: 
 
• Führen Sie das Tagebuch 5 mal am Tag nach, z.B. wenn Sie jetzt wieder zur Arbeit kommen, am Abend, wenn Sie von 
der Arbeit nach Hause kommen, bevor Sie zu Bett gehen, nach dem Aufstehen und bevor sie uns das Aufnahmegerät 
zurücksenden. 
 
• Kreuzen Sie die Kreise an:    Ο 
 
• Wenn Sie eine Tätigkeit länger als 15 Minuten ausführen oder sich länger an einem Ort aufhalten, können Sie die Kreise 
mit Linien verbinden.  
Ο 
        Ο 
        Ο 
 
• Fahren Sie nach 24:00 Uhr auf der ersten Seite des Tagebuches weiter. 
 
Erläuterungen: 
 
Tätigkeit: 
- Als Erinnerungsstütze können Sie in der dafür vorgesehenen Kolonne Ihre Tätigkeit kurz beschreiben. Dies ist jedoch 
freiwillig. 
 
Aktivitätsgrad: 
 Kreuzen Sie wenigstens einen Aktivitätsgrad an. 
- Sehr anstrengend: Sie schwitzen und sind erschöpft, z.B. Aerobics, schnelles Velofahren, Jogging 
- Mässig anstrengend: z.B. Haushalten, Gehen, gemütliches Velofahren 
- Wenig anstrengend: z.B. Stehen, Büroarbeit, Sitzen, Telefonieren, Autofahren 
- Ruhe: Liegen oder Schlafen 
 
Ort: 
Kreuzen Sie wenigstens einen Ort an. Wenn Sie während eines 15-Minuten-Abschnittes sowohl draussen als auch 
drinnen waren, dann kreuzen Sie beides an. 
 
Konsum: 
Tragen Sie die Anzahl Tassen oder Gläser des konsumierten Getränkes in die entsprechende Kolonne ein. 
 
Rauchen: 
- Kreuzen Sie das Feld „selber“ an, falls Sie während diesem Zeitabschnitt geraucht haben (Zigarette, Zigarre, Pfeife etc.) 
- Kreuzen Sie das Feld „gleicher Raum“ an, falls jemand in Ihrer Umgebung in einem geschlossenen Raum eine Zigarette, 
Zigarre, Pfeife etc. raucht. 
 
Medikamente: 
Tragen Sie in dieser Kolonne den Namen und die Dosierung der eingenommenen Medikamenten ein. 
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2. Teil Fragebogen 
 
 
Bitte beantworten Sie diese Fragen am Morgen nach dem Aufstehen. 
 
 
 
Wann sind Sie eingeschlafen? (Möglichst genaue Zeitangabe) 
 
 
_ _ : _ _ Uhr 
Wann sind Sie aufgewacht? (Möglichst genaue Zeitangabe) 
 
 
 _ _ : _ _ Uhr 
Wie lange haben Sie vergangene Nacht gebraucht um einzuschlafen?  
_ _ _ Minuten 
Wie oft sind Sie nachts erwacht?  
 
_ _ _ Mal 
Wie lange sind Sie heute Nacht insgesamt wach gelegen (ohne Einschlafzeit)?  
 
 
_ _ _ Minuten 
Wie würden Sie die Qualität des Schlafes im Vergleich zu Ihrem gewöhnlichen Schlaf einschätzen? (Kreisen Sie das 
Zutreffende an. 1: sehr viel schlechter als gewöhnlich, 5: wie gewöhnlich, 10: sehr viel besser als gewöhnlich) 
 
Unruhiger als gewöhnlich 1  2  3  4  5  6  7  8  9  10 Ruhiger als gewöhnlich  
 
Mehr Wachphasen als 
gewöhnlich 
1  2  3  4  5  6  7  8  9  10 Weniger Wachphasen als gewöhnlich 
 
Bewerten Sie, wie stark der Verkehrslärm während der vergangenen Nacht Ihren Schlaf gestört hat (1: keine Störung; 10 
extreme Störung) 
 
1  2  3  4  5  6  7  8  9  10 
 
 
 
 
 
Wann haben Sie die EKG-Aufzeichnung beendet? ________________ Uhr 
 
 
 
 
 
 
 
 
 
 
 
Besten Dank fürs Mitmachen! 
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8.6 Percentile curves 
 
Percentile of HF for healthy men and women 
 
 
Percentile of LF for healthy men and women 
 
APPENDICES  82 
Percentile of VLF for healthy men and women 
 
Percentile of ULF for healthy men and women 
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 Supplementary material to paper 2 
 
Supplementary Table 1. Unadjusted geometric mean HRV according to ETS exposure 
HRV variable no current ETS exp. ETS < 2 hrs/d ETS > 2 hrs/d 
n 1034 104 80 
SDNN [ms] 134.1 
(131.9, 136.3) 
132.5 
(125.8, 139.5) 
129.3 
(121.9, 137.2) 
Total Power [ms2] 3874.1 
(3732.7, 4020.9) 
3621.5 
(3220.8, 4072.0) 
3294.4 
(2882.1, 3765.6) 
HF [ms2] 
 
71.1 
  (67.3, 75.1) 
62.8 
(52.8, 74.6) 
71.9 
 (59.1, 87.6) 
LF [ms2] 
 
231.8 
 (221.3.0, 242.8) 
214.9 
(185.8, 248.7) 
212.7 
 (180.1, 251.2) 
LF/HF 
 
3.3 
 (3.1, 3.4) 
3.4 
(3.0, 3.9) 
3.0 
(2.6, 3.4) 
VLF [ms2] 
 
624.1 
(600.0, 649.2) 
602.5 
(532.1, 682.2) 
579.8 
 (503.2, 668.0) 
ULF [ms2] 2751.4 
(2641.6, 2865.7) 
2576.1 
(2265.8, 2929.0) 
2255.6 
 (1948.5, 2611.1) 
Values in parentheses are 95% CIs. 
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Supplementary Table 2. Adjusteda geometric mean HRV according to ETS exposure, stratified by sex 
HRV variable no current ETS exp. ETS < 2 hrs/d ETS > 2 hrs/d 
 Men Women Men Women Men Women 
n 479 557 51 53 39 41 
SDNN [ms] 136.9 
(133.7, 140.2) 
131.5 
(128.7, 134.3) 
137.4 
(127.6, 147.9) 
130.3 
(121.6, 139.6) 
127.9 
(117.6, 139.2) 
130.9 
(121.0, 141.6) 
Total Power [ms2] 3981.9 
(3766.7, 4209.4) 
3775.8 
(3603.2, 3957.9) 
3549.5 
(2985.8 ,4219.7) 
3798.4 
(3254.1, 4433.7) 
3556.28 
(2921.7, 4328.7) 
3038.3 
(2548.3, 3622.6) 
HF [ms2] 
 
68.3 
  (62.9, 74.2) 
74.2 
(69.1, 79.7) 
53.6 
(41.4, 69.3) 
68.5 
(54.2, 86.6) 
69.3 
 (51.7, 92.9) 
71.3 
(54.6, 93.1) 
LF [ms2] 
 
270.6 
 (253.7, 288.7) 
205.7 
(194.6, 217.5) 
230.1 
(188.2, 281.3) 
192.8 
(160.6, 231.4) 
230.9 
 (183.8, 290.2) 
172.8 
(140.4, 212.7) 
LF/HF 
 
4.0 
 (3.8, 4.2) 
2.8 
(2.6, 2.9) 
4.3 
(3.6, 5.1) 
2.8 
(2.4, 3.3) 
3.3 
(2.7, 4.1) 
2.4 
(2.0, 2.9) 
VLF [ms2] 
 
698.2 
(658.6, 740.2) 
570.7 
(544.7, 598.1) 
638.0 
(531.9, 765.3) 
554.4 
(475.4, 646.4) 
670.9 
 (545.7, 825.0) 
474.8 
(398.7, 565.4) 
ULF [ms2] 2723.5 
(2560.3, 2897.1) 
2761.3 
(2622.1, 2907.89 
2442.6 
(2015.2, 2960.7) 
2843.7 
(2399.5, 3370.2) 
2368.0 
 (1903.1, 2946.6) 
2172.7 
(1791.0, 2635.7) 
aAdjusted for study site, age, education, BMI, diabetes, and beta-blocker intake. 
Values in parentheses are 95% CIs. 
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Supplementary Table 3. Unadjusted means of heart rate and blood pressure according to ETS exposure 
Variable no current ETS exp. ETS < 2 hrs/d ETS > 2 hrs/d 
heart rate [bpm] 73.4 
(72.8, 73.9) 
73.3  
 (71.6, 75.0)  
75.8 
(73.8, 77.7) 
SBP [mmHg] 132.7 
(131.5, 133.9) 
133.7 
(129.9, 137.5) 
131.5 
(127.1, 135.8) 
DBP [mmHg] 81.7 
(81.0, 82.3) 
82.4 
(80.4, 84.5) 
83.5 
(81.1, 85.9) 
Values in parentheses are 95% CIs. 
SBP: systolic blood pressure, DBP: diastolic blood pressure. 
 
 
Supplementary Table 4. Adjusteda geometric means of heart rate and blood pressure according to ETS exposure, stratified by sex 
Variable no current ETS exp. ETS < 2 hrs/d ETS > 2 hrs/d 
 Men Women Men Women Men Women 
heart rate [bpm] 72.3 
(71.4, 73.1) 
74.3 
(73.7, 75.0) 
72.4  
 (69.8, 74.9)  
74.5 
(72.3, 76.6) 
74.1 
(71.2, 77.0) 
76.4 
(73.9, 78.8) 
SBP [mmHg] 136.9 
(135.2, 138.7) 
129.0 
(127.6, 130.5) 
138.0 
(132.8, 143.2) 
129.6 
(125.0, 134.2) 
137.5 
(131.5, 143.4) 
128.7 
(123.4, 134.0) 
DBP [mmHg] 84.0 
(83.1, 85.0 
79.8 
(78.9, 80.6) 
84.8 
(81.9, 87.6) 
79.8 
(77.1, 82.4) 
85.0 
(81.7, 88.2) 
82.1 
(79.1, 85.1) 
Values in parentheses are 95% CIs. 
SBP: systolic blood pressure, DBP: diastolic blood pressure. 
a Adjusted for study site, age, education, BMI, diabetes, and beta-blocker intake. 
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Supplementary Table 5. Sensitivity analyses including or excluding additional variables into 
the model, with the natural logarithm of total power as outcome variable 
 Effect estimatea 95% CI P 
Baseline analysisb -9.1% -17.4%−-0.1% 0.048 
including exercisec -8.8% -17.0%−0.3% 0.058 
including alcohold -9.0% -17.3%−0.2% 0.054 
including hypertension -8.7% -16.9%−0.4% 0.06 
incl. cardiovascular risk markers in the bloode -8.5% -16.8%−0.6% 0.067 
including CO -9.1% -17.4%−-0.1% 0.048 
excluding education -9.3% -17.5%−-0.3% 0.044 
excluding subjects with medication intakef -10.2% -18.7%−-0.9% 0.033 
a Estimated %-increase in total power associated with exposure to ETS at home or at work (as 
compared to no exposure to ETS at home or at work), adjusted for sex, age, age squared, study site, 
education, diabetes and beta-blocker 
b adjusted for sex, age, age squared, study site, education, diabetes and beta-blocker 
c physical exercise causing sweating and physical exercise causing slight shortness of breath 
d consumption of red wine and alcoholic beverages 
e serum levels of uric acid, high sensitive C-reactive protein and non-HDL-cholesterol 
f ACE inhibitors, antiarrhythmic medication, calcium channel blockers, diuretics or sympathomimetics 
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8.7 Supplementary material to paper 3 
 
Supplementary Figure. Curves of adjusted geometric means of SDNN for the three 
exercise categories with BMI as independent variable being continuousa 
 
 a adjusted for sex, age, age squared, study site, education, diabetes, hypertension, beta-blocker intake 
and smoking status in a cubic model for BMI 
 
 
Supplementary Table 1. Interaction terms between body mass index and physical activity in 
their effect on the natural logarithm of SDNN 
BMI normal weight overweight obese 
 Coefficient  P Coefficient  P Coefficient  P 
no regular exercise 0.128 0.000 0.105 0.000 Ref. - 
½ - 1 h/week exercise -0.067 0.104 -0.072 0.071 0.092 0.006 
≥2 h/week exercise -0.125 0.006 -0.109 0.014 0.173 0.000 
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Supplementary Table 2. Adjusteda geometric mean (GM) of night-time HRV in different exercise categories 
BMI normal weight overweight obese 
 Exercise [h/week] GM 95% CI GM 95% CI GM 95% CI 
SDNN [ms] None 79.3 (76.4, 82.2 81.2 (78.5, 84.1) 77.0 (73.6, 80.6) 
½ - 1  83.9 (80.5, 87.4) 81.8 (78.8, 85.0) 82.5 (78.1, 87.2) 
≥ 2 85.8 (82.0, 89.8) 86.7 (83.0, 90.5) 88.6 (82.9, 94.6) 
Total power [ms2] None 1304.4 (1208.2, 1408.3) 1353.7 (1261.2, 1453.0) 1206.4 (1098.8, 1324.6) 
½ - 1 1462.7 (1342.9, 1593.1) 1421.5 (1315.7, 1535.7) 1423.6 (1270.9, 1594.6) 
≥ 2 1450.8 (1321.0, 1593.3) 1516.3 (1386.6, 1658.2) 1578.9 (1378.6, 1808.3) 
HF [ms2] None 104.3 (92.9, 117.0) 114.8 (103.2, 127.7) 108.8 (94.5, 125.2) 
½ - 1 106.3 (93.4, 120.9) 106.7 (94.9, 119.9) 131.9 (111.1, 156.4) 
≥ 2 104.0 (90.3, 119.8) 132.0 (115.4, 151.1) 150.2 (122.4, 184.2) 
LF [ms2] None 261.0 (238.1, 286.0) 281.2 (258.4, 306.1) 241.5 (215.9, 270.0) 
½ - 1 313.7 (283.2, 347.4) 290.7 (265.0, 318.9) 286.0 (249.7, 327.5) 
≥ 2 305.1 (272.8, 341.4) 314.7 (282.8, 350.3) 309.8 (263.4, 364.4) 
LF/HF None 3.2 (2.9, 3.4) 3.2 (3.0, 3.4) 3.0 (2.7, 3.3) 
½ - 1 3.7 (3.4, 4.0) 3.4 (3.2, 3.7) 2.8 (2.5, 3.2) 
≥ 2 3.7 (3.4, 4.1) 3.1 (2.8, 3.3) 2.6 (2.3, 3.0) 
a adjusted for sex, age, age squared, study site, education, diabetes, hypertension, beta-blocker intake and smoking status 
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